



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

The equine mononuclear phagocyte system: the relevance of the horse as a model for understanding human innate immunity

Citation for published version:

Karagianni, A, Lisowski, Z, Hume, D & Pirie, S 2020, 'The equine mononuclear phagocyte system: the relevance of the horse as a model for understanding human innate immunity', *Equine Veterinary Journal*. <https://doi.org/10.1111/evj.13341>

Digital Object Identifier (DOI):

[10.1111/evj.13341](https://doi.org/10.1111/evj.13341)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Publisher's PDF, also known as Version of record

Published In:

Equine Veterinary Journal

Publisher Rights Statement:

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
© 2020 The Authors. Equine Veterinary Journal published by John Wiley & Sons Ltd on behalf of EVJ Ltd

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



REVIEW ARTICLE

The equine mononuclear phagocyte system: The relevance of the horse as a model for understanding human innate immunity

Anna E. Karagianni¹  | Zofia M. Lisowski¹  | David A. Hume^{2*} | R. Scott Pirie^{1*}

¹The Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Midlothian, UK

²Mater Research Institute-UQ, Translational Research Institute, Woolloongabba, QLD, Australia

Correspondence

Anna E. Karagianni, The Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Easter Bush, Midlothian, EH25 9PS, UK.
Email: anna.karagianni@roslin.ed.ac.uk

Funding information

A.E. Karagianni is funded by the Horserace Betting Levy Board. D.A. Hume is supported by The Mater Foundation.

Abstract

The mononuclear phagocyte system (MPS) is a family of cells of related function that includes bone marrow progenitors, blood monocytes and resident tissue macrophages. Macrophages are effector cells in both innate and acquired immunity. They are a major resident cell population in every organ and their numbers increase in response to proinflammatory stimuli. Their function is highly regulated by a wide range of agonists, including lymphokines, cytokines and products of microorganisms. Macrophage biology has been studied most extensively in mice, yet direct comparisons of rodent and human macrophages have revealed many functional differences. In this review, we provide an overview of the equine MPS, describing the variation in the function and phenotype of macrophages depending on their location and the similarities and differences between the rodent, human and equine immune response. We discuss the use of the horse as a large animal model in which to study macrophage biology and pathological processes shared with humans. Finally, following the recent update to the horse genome, facilitating further comparative analysis of regulated gene expression between the species, we highlight the importance of future transcriptomic macrophage studies in the horse, the findings of which may also be applicable to human as well as veterinary research.

KEYWORDS

horse, macrophage, monocyte, immunity, animal model

1 | INTRODUCTION

Horses are already recognised as models for several human diseases, including metabolic syndrome, asthma, musculoskeletal diseases,

melanoma and autoimmune uveitis.¹⁻⁶ More than 100 equine hereditary conditions may serve as models for human disorders, including inflammation, muscular or fertility disorders, osteoarthritis and even depression.⁷⁻¹⁰ The horse has the potential to represent an appropriate

Abbreviations: AM, alveolar macrophage; BAL, bronchoalveolar lavage; BMDMs, bone marrow-derived macrophages; CSF1, colony-stimulating factor 1; CSF1R, colony-stimulating factor 1 receptor; CSF2, colony-stimulating factor 2; CXCL10, C-X-C motif chemokine ligand 10; FLT3L, FMS-like tyrosine kinase 3 ligand; GIT, gastrointestinal tract; ICC, interstitial cells of Cajal; IFN, interferon; IL-10, interleukin-10; IMs, interstitial macrophages; LpM, lamina propria macrophages; MIP-2, macrophage inflammatory protein 2; MM, muscularis macrophages; MMEA, mild to moderate equine asthma; MP, myenteric plexus; MPS, mononuclear phagocyte system; NO, nitric oxide; PBMC, peripheral blood mononuclear cells; PIMs, pulmonary intravascular macrophages; PM, peritoneal macrophage; POI, post-operative ileus; Poly IC, polyinosinic polycytidylic acid; PRR, pattern recognition receptor; SEA, severe equine asthma; TRAF1, TNF receptor-associated factor 1; TRIF, TIR-domain-containing adapter-inducing interferon- β .

*Senior co-authors.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2020 The Authors. *Equine Veterinary Journal* published by John Wiley & Sons Ltd on behalf of EVJ Ltd

large animal model in which to study basic macrophage biology and pathological processes shared with humans, with the advantage that insights can be applied in both veterinary and human medicine.

Monocytes and macrophages provide the first line of defence against pathogens and play a crucial role in both health and disease.¹¹ Macrophage biology has been studied most extensively in mice, with the data derived from such studies having undoubtedly helped to unravel basic physiological mechanisms in health and disease processes. However, direct comparison of mouse and human macrophages has revealed many functional differences.^{12,13} In contrast, important similarities have already been described between horse and human macrophages.¹⁴⁻²² In this review, we provide an overview of equine macrophage biology and highlight the importance of future macrophage studies in the horse, the findings of which may also be applicable to man.

2 | AN OVERVIEW OF MACROPHAGE BIOLOGY AND THE MONONUCLEAR PHAGOCYTE SYSTEM IN HUMANS AND RODENTS

Macrophages (from Greek 'μακρόν' meaning big and 'φαγείν' meaning to eat) are large leucocytes that comprise 10%-15% of all cells in most organs of all animal species.²³⁻²⁵ They were originally identified in the 19th century by Metchnikoff, who distinguished them from related microphages, now known more commonly as granulocytes or polymorphonuclear leucocytes. Subsequently, van Furth and Cohen and others recognised the functional relationship between bone marrow progenitors, circulating blood monocytes and resident tissue macrophages and proposed the concept of a mononuclear phagocyte system (MPS).^{26,27} The shared functions of cells of the MPS include antigen presentation, phagocytosis, cytokine production, microbicidal activity, tissue repair and the general regulation of tissue homeostasis (Figure 1).

Over the past 5 years there have been numerous studies on the development of the MPS in the mouse. Macrophage-like cells first




FIGURE 1 Summary of macrophage functions

appear in the yolk sac without an evident monocyte-like intermediate, and thence are produced in the fetal liver (reviewed in 28,29). Furthermore, lineage-trace studies suggest that many tissue macrophage populations (the notable exception being the large macrophage population of the intestinal mucosa) are derived from fetal progenitors and maintained in the steady state without substantial input from blood monocytes.³⁰⁻³⁵ The tissue itself plays an important role in controlling the balance between the persistence of the resident macrophage population and the recruitment of circulating monocytes at various stages of its maturation.³¹ Humans with mutations in the IRF8 transcription factor lack blood monocytes, yet have tissue macrophages.³⁶ Although these results are often portrayed as a contradiction to the MPS concept, the original definition of the MPS clearly did recognise the ability of resident macrophages to self-replicate.²⁹ Many studies in multiple organ systems have shown that blood monocytes can, and do, occupy the vacant territories of resident macrophages when these cells are depleted (reviewed in 28,29,31,37). It is important to recognise that the lineage-trace models that favour the persistence of fetal-derived macrophages are open to interpretation.^{29,37} Furthermore, the recent concepts of MPS ontogeny and homeostasis are derived mainly from a single inbred mouse strain (C57Bl6) under specified pathogen-free laboratory conditions. It is not yet clear that the conclusions derived from these studies can be applied even to other mouse strains let alone other species, including the horse.^{29,37,38}

Although all tissue macrophages share many surface and intracellular markers and a characteristic ramified or stellate morphology, they also adapt their function and gene expression to perform specific functions. For example, hepatic and splenic macrophages, which have direct contact with the blood, are adapted for erythrophagocytosis and recycling of iron, whereas a population of bone marrow macrophages is adapted to support erythropoiesis in erythroblastic islands.³⁹ Embryonic macrophages have a common gene expression profile, with tissue-specific macrophage adaptation arising mainly in the early postnatal period, in parallel with cessation of the major proliferative phase and appearance of organ-specific functions.^{40,41} Adaptation is driven in part by expression of specific transcriptional regulators.⁴⁰ For example, two recent studies described in detail the adoption of liver macrophage (Kupffer cell)-specific gene expression profiles by monocytes recruited following Kupffer cell depletion, thus emphasising the roles of transcription factors *Id3* and *Nr1h3*.^{42,43} Macrophages may even adapt to multiple specific niches within tissues. For example, Chakarov *et al.* noted that subpopulations of macrophages expressing the surface marker *Lyve1* are associated specifically with capillaries in the lung and several other tissues.⁴⁴ Figure 2 summarises some of the specific subpopulations that have been described in mouse tissues. Recent studies of tissue-specific macrophage populations are reviewed in Hume *et al.*²⁹

Whether or not these resident macrophage populations are replenished by monocytes in the steady state, monocytes are recruited to tissues in response to inflammatory stimuli. The gene




FIGURE 2 Main types of cells comprising the mononuclear phagocyte system in adult mammals

expression profiles of inflammatory monocytes/macrophages differ depending upon the nature of the inflammatory stimulus and change with time as the stimulus is removed and normal homeostasis is restored. Based upon a parallel with the Th1/Th2 dichotomy in T cells, there is a prevalent view that macrophage ‘activation’ can be divided into M1 or classical (mediated by the Th1 lymphokine, INF γ) or M2 or alternative (mediated by the Th2 lymphokines, IL-4/IL-13). This dichotomy is not supported by transcriptomic analysis, which also reveals that few markers of M1/M2 divergence are conserved from mouse to human.^{11,45,46} Recent reviews support a much wider spectrum of activation states and also the concept of innate immune memory, wherein macrophages retain an epigenetic imprint of previous exposure to a stimulus such as microorganisms.⁴⁷

The development and maintenance of the MPS depends upon macrophage colony-stimulating factor 1 receptor (CSF1R) and its two ligands, macrophage colony-stimulating factor 1 (CSF1, also known as M-CSF) and interleukin 34 (IL-34). Mutations of the *Csf1r* in mice, rats and humans are associated with global deficiencies of tissue macrophage populations and multi-system developmental abnormalities, including severe postnatal growth retardation (reviewed in 48). Many of these deficiencies manifest in mice and rats with *Csf1* mutations, whereas IL-34 appears to be involved specifically in the development of macrophages of the brain (microglia) and skin (Langerhans cells).⁴⁹ The requirement for *Csf1r* for survival of resident macrophages is retained in adults and blocking CSF1R leads to progressive depletion of most macrophage populations.^{50,51} Conversely, treatment of mice, rats or pigs with recombinant CSF1 leads to a monocytosis as well as proliferative expansion of resident macrophage populations.⁵²⁻⁵⁵ These findings, combined with the fact that macrophages of the liver and spleen are the main site of

clearance of CSF1, led to the concept of homeostatic control of the entire MPS via the availability of CSF1.³⁷ The exception to this concept is the lung, where another growth factor, granulocyte-macrophage colony-stimulating factor 2 (CSF2, also known as GM-CSF), is uniquely required for both development and resident macrophage homeostasis.⁵⁶

In this review, we will describe the most studied components of the MPS of the horse (Figure 3) and highlight the effect of the microenvironment on macrophage function and phenotype. Finally, we will discuss the potential value of the horse in providing a greater understanding of macrophage biology in humans.




FIGURE 3 Monocyte and macrophage populations in the horse. This figure illustrates key monocyte and macrophage populations based on studies in the horse. Macrophages in horses have been identified by a combination of cell surface markers, including CD14 and CD163, although studies and reagents are limited in number. Macrophages in different tissues express different levels of cell surface proteins highlighting the diversity in resident macrophage populations. Bone marrow-derived macrophages, which are cultured from haematopoietic progenitor cells collected from bone marrow, express CD14. Monocytes isolated from peripheral blood mononuclear cells (PBMC) using a density gradient express CD14, CCL2 and CCL3, whereas monocyte-derived dendritic cells cultured in CSF2 and IL-4 express only low levels of CD14 and CD86 compared to monocytes, but express the dendritic cell markers FLT3 and CD206. Other markers used to characterise equine dendritic cells include CD172a MHC class II, CD44, CD163, CD204 and Bla36 (*not shown in figure*). Intestinal and peritoneal macrophages all express CD163. It is not known if intestinal macrophages express CD14 in the horse, although peritoneal macrophages do not. Alveolar macrophages express CD14, CD163, TLR2, TLR3, TLR4 and TLR9, while pulmonary intravascular macrophages have high expression of TLR4 and TLR9. Equine pulmonary interstitial macrophages have been shown to express TLR9 by immuno-electron microscopy

3 | THE MONONUCLEAR PHAGOCYTE SYSTEM OF THE HORSE

3.1 | Bone marrow-derived macrophage differentiation and activation in the horse

Bone marrow-derived macrophages (BMDMs) are primary macrophage cells generated in cell culture. They are derived from progenitor cells and in the presence of the macrophage lineage-specific growth factor CSF1 they differentiate and proliferate into macrophages.⁵⁷ In mice, macrophages are routinely generated in vitro from bone marrow progenitors for subsequent functional studies.^{58,59} This approach has recently been extended to large animal species expedited by the capacity to freeze cells for future culture following recovery.^{21,60-62} We have recently published a comparative analysis of RNA-seq data of horse BMDM and their response to lipopolysaccharide (LPS) with similar data for ruminants (sheep, goat, cow and water buffalo), pig, mouse and rat (in press). The analysis reveals conservation of the underlying transcription factor repertoire, basal macrophage-specific gene expression and LPS-inducible cytokines. However, all of the large animals are clearly distinguished from rodents, and horse macrophages have a small set of species-specific macrophage-expressed transcripts that will be the subject of future studies.

Similar to other groups,⁶³⁻⁶⁵ we have also differentiated equine monocytes to macrophages in the presence of horse serum which, among other stimuli, contains CSF1 (A.E. Karagianni, 2014, unpublished data). Bone marrow colony assays have been described using horse marrow and used to study the transforming actions of equine infectious anaemia virus.⁶⁶ Furthermore, a macrophage cell line (e-CAS cells) has been derived from equine bone marrow cells⁶⁷ and subsequently shown to have phagocytic capabilities and responsiveness to CSF2 and LPS. However, potential problems associated with cell lines include contamination by other cells or microorganisms,⁶⁸ which can result in molecular and cellular changes in the cell line.⁶⁹ These problems have very recently been highlighted by Evans et al,⁷⁰ who sequenced the e-CAS cell line and found the cells to likely be of mouse rather than horse origin. Finally, equine bone marrow-derived mononuclear cells have also been used in cell therapy methodologies in horses affected with equine asthma, whereby intratracheal administration ameliorates the inflammatory response in the lungs, resulting in beneficial effects on clinical signs.⁷¹ Similar observations have already been reported in mice.⁷²

3.2 | Monocyte differentiation and activation in the horse

Based mainly on murine literature, during postnatal life, monocytes can replace resident macrophages in all major organs and acquire their gene expression profile.²⁹ They share the expression of several surface markers with macrophages and together with dendritic cells (DCs), act as antigen-presenting cells and play a vital role during infection.²⁹ Several studies in multiple organs have found that blood

monocytes can occupy the vacant territories of tissue macrophages when these populations are depleted (reviewed in 28,29,31,37). In the horse, similar to other well-studied species, blood is more easily sampled than bone marrow. Consequently, several studies have been conducted on equine monocytes isolated from peripheral blood mononuclear cells (PBMC), focusing on their ability to produce proinflammatory cytokines, such as TNF and IL-1, under various conditions, including LPS stimulation.⁷³⁻⁷⁹ Raabe et al⁶⁴ also demonstrated the transforming actions of equine infectious anaemia virus on equine blood monocytes. Others have shown that equine peripheral blood monocytes and monocyte-derived macrophages express CXCL10, a Th1 marker, in response to IFN- γ stimulation.^{80,81} The induction of equine CXCL10 by IFN- γ is also in agreement with human and murine studies.^{82,83}

Compared to alveolar macrophages (AMs), equine PBMC appear more sensitive to low concentrations of LPS, a finding which may reflect desensitisation of AMs by chronic low-level stimulation with inhaled proinflammatory agents.⁸⁴ In humans and mice, the macrophage response to LPS can be mediated via two different pathways; a myeloid differentiation primary response gene 88 (MyD88)-dependent pathway, which induces an inflammatory response, and/or a MyD88-independent pathway (also known as the TIR-domain-containing adapter-inducing interferon- β [TRIF] pathway), which stimulates the induction of type I interferon (IFN) and IFN-inducible genes.^{85,86} These pathways appear to be conserved in horses (Figure 4). In equine macrophages/monocytes, the induction of genes encoding *TNF*, *IL1B* and *IL6* was linked to activation of the MyD88 pathway, whereas *IFNA*, C-X-C motif chemokine ligand 10 (*CXCL10*) and *RANTES* (also known as *CCL5*) were related to the TRIF-dependent signalling pathway.⁸⁷ Even high concentrations of LPS failed to significantly activate TRIF-dependent gene expression of *IFN*, *CXCL10*, *RANTES* or *TNF* receptor-associated factor 1 (*TRAF1*) in equine monocytes, suggesting that in contrast to other studied mammalian-derived cells, the response of equine monocytes to LPS mainly occurs via the MyD88 pathway.⁸⁷ Furthermore, Ahn et al⁸⁸ studied the response of equine PBMC to well-known inflammasome activators in other species (including human and mouse), whereby equine PBMC were shown to secrete IL-1B, a well-known indication of inflammasome activation. Based on comparative studies, the authors indicated that equine inflammasome activation is similar to that in humans, mice and pigs.

As demonstrated in other mammalian-derived cells, TLR2 ligands induce a mild inflammatory response in equine PBMC; this is in comparison to the much greater response to TLR4 agonists.^{9,89} Recent transcriptomic studies have reported that LPS induces differential microRNA expression in equine PBMC in a manner comparable to humans, thus facilitating interspecies comparative study of the role of microRNAs in the inflammatory cascade during endotoxaemia and sepsis.⁹⁰ Equine monocytes are also responsive to TLR3 stimulation with double-stranded RNA (polyinosinic polycytidylic acid [Poly IC]),⁹¹ which is dependent upon the TRIF adaptor. In contrast, horse monocytes do not express TLR5, thus explaining their lack of response to flagellin.⁹² However, they do express the scavenger




FIGURE 4 TLR 2, 3 and 4 signal transduction pathways of the horse. Recognition of lipoprotein ligand by TLR2 triggers the MyD88-dependent signalling pathway (red arrow). Following stimulation with LPS, lipopolysaccharide binding protein (LBP) is recruited to transfer LPS via the Lipid A component to CD14 on the surface of macrophages/monocytes. This process is followed by the formation of a complex with TLR4 and MD2, activation of NF κ B signalling pathway and cytokine production. In humans and mice, the recognition of the LPS ligand results in a conformational change in the TLR4 receptor triggering a myeloid differentiation primary response gene 88 (MyD88)-dependent pathway and/or a MyD88-independent pathway (also known as the TIR-domain-containing adapter-inducing interferon β (TRIF) pathway). Equine monocytes fail to strongly activate the TRIF pathway in response to LPS (black dashed arrow); instead, they respond mainly via the MyD88-dependent pathway (yellow arrow), resulting in the induction of the proinflammatory cytokines *TNF*, *IL1B*, *IL6* and the anti-inflammatory cytokine *IL10*. In contrast, TLR3 signalling occurs via the TRIF pathway (blue arrow), inducing high expression of *IFN β* , *CXCL10* and *RANTES*

receptor CD163,⁹³ as do equine alveolar and peritoneal macrophages (PMs).²⁰ Moreover, equine monocytes isolated from PBMC using a density gradient express CD14, CD16, CCL2 and CCL3.^{16,94} Unlike humans and horses, mice do not have duplicated CD16 gene, while CD14⁺CD16⁺ have also been detected in humans and horses but not in mice.¹⁶

The MPS includes antigen-presenting DCs. The term DC is loosely applied to any cell that can present antigen to naïve T cells, including bone marrow or monocyte-derived cells cultivated in CSF2. However, there has been increasing recognition that these 'DCs' are distinct from those generated in response to FMS-like tyrosine kinase 3 ligand (FLT3L), a cytokine essential for their development; are derived from a committed DC progenitor⁹⁵ and may be better considered as an alternative state of macrophage differentiation.³⁷

Monocyte-derived equine DCs⁹⁶ have also been generated in various studies by cultivation in CSF2 and found to express different cell markers including FLT3, CD86, CD204, CD206, CD163 and low levels of CD14.⁹⁷⁻¹⁰⁰ Moreover, horse microarrays were used to investigate the gene profile of equine immature and mature DC subsets, confirming the existence of two clearly distinct populations.⁹⁷

In contrast, comparisons between lung and blood-derived DC of the horse showed no morphological differences.¹⁰¹ However, blood-derived DCs expressed higher levels of CD86 and CD172 α than those in the lung, while both expressed MHC class II and CD44 and, to a lower level, the scavenger receptors CD163, CD204 and the B lymphocyte antigen Bla36.¹⁰¹ Furthermore, lung DC demonstrated higher phagocytic activity compared to their blood-derived counterparts.¹⁰¹ Interestingly, others have also reported remarkable age-dependent phenotypic and functional differences between blood monocyte-derived DCs from foals and adult horses.¹⁰² Following bacterial exposure, DCs generated from foals exhibited lower antigen presentation capabilities and produced lower quantities of proinflammatory cytokines. In summary, these results highlight the influence of both cell origin and ageing on both phenotypic and functional characteristics.

3.3 | The role of the equine resident macrophages in intestinal disease

3.3.1 | Resident intestinal macrophages

The gastrointestinal tract (GIT), although internal, has the largest surface area in contact with the external environment of all the body organs and thus receives a vast and constant antigenic challenge. It is therefore not surprising, based on data derived from humans and rodents, that the GIT represents the largest reservoir of mononuclear phagocytes in the body.¹⁰³ They are located throughout all the tissue layers of the intestine and are broadly categorised into two phenotypically distinct groups: mucosal or lamina propria macrophages (LpM) and *muscularis* macrophages (MM).

Lamina propria macrophages are found in the mucosa of the GIT, predominantly in the lamina propria,¹⁰⁴ and in both mice and humans express CD64, MHC class II, CD206 and CD163. In contrast to human LpM, mouse LpM also express CD11b, CD11c and CX3CR1.¹⁰⁵ Given their close proximity to the intestinal lumen and the potential for constant antigenic challenge, it is not surprising that, unlike other tissue macrophages, LpM appear to be in a state of 'hyporesponsiveness'.¹⁰⁶ In humans, this has been attributed to the absence of expression of the LPS receptors CD14¹⁰⁷ and TLR4,¹⁰⁸ the downregulation of TLR2,¹⁰⁸ their inability to produce proinflammatory cytokines, such as TNF α , and the production of the anti-inflammatory cytokine, interleukin-10 (IL-10).^{109,110} In contrast, MM, which are located in the serosa, myenteric plexus and muscle layers of the mouse and human GIT,^{111,112} do express CD14¹¹³ and TLR4¹¹⁴ and may participate in endotoxin-mediated responses within the muscularis. MM in mice and humans also express CD163, MHC class II, CD206 and CD64 with two different subtypes proposed, depending on the state of activation.^{105,115}

Both LpM and MM survival is dependent upon signalling from the CSF1R.^{51,116} Depletion of LpM using an anti-CSF1R antibody resulted in a disruption to the differentiation and proliferation of intestinal epithelial cells,¹¹⁷ while depletion of MM resulted in disruption

of peristalsis in mice, thus demonstrating a role of MM in intestinal motility.¹¹⁶ Studies in mice have shown that MM have a slower turnover rate than LpM;¹¹² although both are derived from both yolk sac and monocytes,³⁵ LpM in both mice and humans are continuously replaced by blood monocytes.^{118,119} This monocyte infiltrate is also important for tissue repair following inflammation, as demonstrated in a mouse model of post-operative ileus (POI).¹²⁰ CD163 has been used to identify mucosal and MM in the horse.¹²¹⁻¹²³ MAC387 has also been used to identify mucosal macrophages in horses, although this nonspecific macrophage marker is also expressed by granulocytes.^{124,125} CD163⁺ macrophages are present in all tissue layers of the equine small and large intestine, although the distribution of cells is not uniform.¹²³ Different cell densities were observed between the different tissue layers (lamina propria, submucosa and muscularis externa). Within the submucosa, there was also a higher density of CD163⁺ cells in the large intestine compared to the small intestine. This increase in density of CD163⁺ cells could be a consequence of the higher increase of bacterial content in the intestinal lumen of the large intestine compared to the small intestine.

The role of macrophages in humans and rodents has been clearly demonstrated in various intestinal pathologies of the GIT, particularly in POI and inflammatory bowel disease (IBD).¹²⁶⁻¹²⁹ Despite both these conditions occurring in horses (reviewed in 130 and 131), the study of macrophage responses in equine intestinal disease is very limited. The identification of macrophages in the cellular infiltrate of equine IBD cases is a criteria considered in the sub-categorisation of disease; macrophage infiltrate is associated with granulomatous enteritis and multisystemic eosinophilic epitheliotropic disease but not with lymphocytic-plasmacytic enterocolitis or idiopathic eosinophilic enterocolitis.¹³⁰ However, these cellular-based disease sub-categories are generally based on haematoxylin and eosin staining; to date, no studies have used specific markers to study different macrophage subpopulations in horses, as has been done in mice¹²⁹ and humans.¹²⁸ Although Little et al¹³² used calprotectin as a macrophage marker in an equine model of intestinal manipulation; calprotectin is also expressed in neutrophils and monocytes. This study did demonstrate an intestinal manipulation-induced local inflammatory response in horses, similar to that of rodents and humans which ultimately leads to smooth muscle dysfunction and POI.^{126,127} Intestinal ischaemia and reperfusion in horses results in an increased phagocytic activity of CD163⁺ macrophages without a change in numbers, suggesting their potential role in the resolution of inflammation¹²¹ and supporting CD163 as a macrophage marker for pro-repair (or M2) macrophages.¹³³ Thus, CD163 expression in resident equine intestinal macrophages¹²³ suggests that the normal equine GIT is populated with intestinal macrophages associated with an anti-inflammatory phenotype. By contrast, human studies have demonstrated a contribution of CD163⁺ cells to the amplification of inflammation in the mucosa in IBD patients.¹³⁴ Furthermore, the proinflammatory mediators, IFN- γ , LPS and TNF, are found to suppress the expression of CD163 in human monocytes,¹³⁵ suggesting that CD163 may be regulated by both pro- and anti-inflammatory mediators. Given the relative sparsity of studies of macrophage

populations of the intestine of the horse, it is difficult to draw conclusions. There remains a need for further study of immune cell populations in the equine GIT and development of additional markers.

3.3.2 | Equine peritoneal macrophages

The peritoneal cavity is another major source of macrophages for functional studies in rodents, in many cases following injection of an irritant or infectious agent.¹³⁶ This anatomical compartment has also been a commonly used source of macrophages in mice. In this species, resident PMs have a unique expression profile dependent upon the transcription factor, *Gata6*.^{137,138} PMs have also been isolated and studied in humans¹³⁹ and pigs.¹⁴⁰ The function of peritoneal-derived macrophages is likely to be influenced by their close proximity to the GIT, potentially acting as a defence against any breach of the integrity of the intestinal wall which may result in exposure to intestinal luminal-derived microflora and various bacterial-derived products.¹⁴¹ One of the genes that is highly expressed in resident macrophages in mice and humans is *Vsig*, encoding the surface receptor CrIG. In humans, CrIG-positive macrophages in the peritoneum are associated with disease severity and susceptibility to infection in patients with liver disease and ascites.^{142,143}

Peritonitis is a significant clinical issue in horses, most commonly associated with surgery for indications such as colic.¹⁴⁴ LPS stimulation of equine PMs induced the significant production of prostanooids and proinflammatory cytokines,¹⁴⁵⁻¹⁴⁷ but did not produce nitric oxide (NO).¹⁷ This LPS-induced response could be suppressed by high concentrations of dexamethasone, as well as by IL-10.^{17,148} Interestingly, LPS-induced TNF production from PMs harvested from healthy horses was significantly increased compared to PMs derived from horses with acute gastrointestinal disease, leading to the suggestion that PMs harvested from the latter group may have developed early endotoxin tolerance in response to disease-associated endotoxaemia.¹⁴⁹ However, in this study there was marked horse-to-horse variation, and the authors relied on measuring TNF bioactivity rather than protein expression.

We have also reported on the failure of equine PMs, immediately isolated from euthanised horses, to produce TNF in response to LPS, Poly IC and heat-killed *S. typhimurium* stimulation. This cell population expressed both CD163 and TLR4, but not CD14.²⁰ Other studies also reported that the LPS responsiveness of equine PMs was neither dose- nor time-dependent, as assessed by a TNF bioassay.^{17,146,148} Previous studies on the LPS responsiveness of equine PMs used cells harvested from live horses, whereby peritoneal fluid is collected from the most dependent abdominal site of standing subjects, likely containing a PM population which has gravitated at this location.^{17,146,148} In contrast, the collection procedure we adopted to harvest PMs from euthanised horses involved high volume lavage of the entire abdominal cavity, potentially resulting in the isolation of a PM population more representative of the entire abdominal cavity including those loosely adherent to the peritoneum. Finally, site-dependent differences in the differential gene expression of

AMs and PMs derived from euthanased horses also supported the influence of the tissue microenvironment on macrophage function and phenotype.²²

3.4 | Pulmonary macrophages: key players in the immune defence of the equine lung

At least three types of macrophages have been identified so far in the lungs: the AMs, the interstitial macrophages (IMs) and the pulmonary intravascular macrophages (PIMs). PIMs are absent in healthy humans and mice, but are present in horse, sheep and other species.^{150,151} Published studies, mainly in mice, have differed in their conclusions with respect to the existence of significant functional differences between these populations of lung macrophages.¹⁵²⁻¹⁵⁶ As bronchoalveolar lavage (BAL) is a practical and commonly used method of obtaining resident airway cells, there are several published transcriptome analyses of BAL-derived AMs in different species, including large animals such as pigs,¹⁵⁷ sheep⁶¹ and horses.²² They are clearly distinct from other tissue macrophages, expressing many lectin-like receptors apparently adapted to recognise, internalise and eliminate inhaled microorganisms. The resident AMs arise during embryogenesis and self-renew throughout life without major replacement from circulating monocytes.³² However, yolk sac-derived monocytes/macrophages, blood monocytes or bone marrow transplanted into *Csf2r^{-/-}* mice can re-establish the missing population and successfully differentiate to AMs.¹⁵⁸

In comparison, IMs are located in the bronchial and not the alveolar interstitium and more closely resemble blood monocytes and are therefore clearly distinct from AMs.^{151,156} Moreover, recent transcriptomic studies also described three newly identified IM subsets in the murine lung at steady state.¹⁵⁶ Despite the functional, morphological and transcriptional differences between these two cell types, both are essential for lung homeostasis and immune responses.^{151,154}

Although most equine-based studies have focused on the function of AMs and their response to various stimuli, more recently, Lee et al¹⁰¹ studied the different subpopulations of myeloid cells in equine lung tissue. This latter study highlighted the differences and similarities in the function and phenotype of lung and blood myeloid cells. Both interstitial and AMs are thought to contribute to airway inflammation. For example, in severe equine asthma (SEA), a common environmental respiratory disease in adult horses, certain hay dust-derived components, including endotoxin and fungal spores, activate macrophages, resulting in the induction of chemokines, such as IL-8 and macrophage inflammatory protein 2 (MIP-2) or CXCL2^{159,160} and the subsequent recruitment of neutrophils to the airway.¹⁶¹⁻¹⁶⁷ This neutrophil accumulation in turn leads to free radical and protease-mediated tissue damage, a process also seen in human studies.¹⁶⁸⁻¹⁷⁰

Respiratory infections or airway inflammation are very common in horses; even subtle inflammatory responses within the airway can have important consequences, particularly in equine athletes.^{171,172} Racehorses commonly develop airway inflammation during training,

with prevalence rates as high as 70%-80%.^{173,174} Lung macrophages may be the primary or secondary site of infection and/or the source of inflammatory cytokines in several important infectious and non-infectious equine diseases, including equine arteritis virus, equine influenza, equine herpesvirus 2 and both mild to moderate equine asthma (MMEA) and SEA.^{65,159,175-177}

Moreover, a few studies have assessed the influence of training on immune cell function specifically within the lung, a key consideration in light of the recently reported disassociation between the response of equine monocytes and AMs to training.¹⁷⁸ Both an exercise-associated reduction in equine AM phagocytic capacity¹⁷⁹ and a training-associated derangement in the responsiveness of equine AMs to various TLR ligands have been reported, theoretically reflecting an increased susceptibility to opportunistic infection.¹⁷⁸ In agreement, we recently demonstrated a training-associated alteration in equine AM basal gene expression, which was also consistent with a degree of immunosuppression at the level of the airways.¹⁸⁰

Bacteria, such as *Streptococcus zooepidemicus*, *Streptococcus pneumoniae* and *Pasteurella/Actinobacillus species*, constitute opportunistic pathogens in the equine airway, triggering the respiratory immune system and inducing inflammation.^{181,182} Exposure to other factors, such as *Aspergillus fumigatus* and hay dust, have also been shown to induce an inflammatory response via the activation of AMs.¹⁸³ LPS, a significant component of organic dust derived from equine bedding and forage, is considered a major factor in the induction of airway inflammation in stabled horses.¹⁸³ Werners and Bryant¹⁸⁴ reviewed the limited literature relating to structure-function relationships among pattern recognition receptors (PRRs) in horses. Early studies found that equine AMs produced large amounts of TNF in response to LPS, but were significantly less responsive to bacterial LPS than blood monocytes, requiring 100-fold higher concentration to induce procoagulant activity.⁸⁴ Subsequently, Suri et al¹⁸⁵ demonstrated that TLR4, but not TLR2, is constitutively expressed in healthy horse lungs, with TLR2 being induced by LPS in IMs, a finding also reported in murine, human and porcine macrophages.^{12,186,187} It is likely that increased expression of *TLR2* is a consequence of TLR4 signalling in response to LPS, as shown in mice.¹⁸⁸ More recently, Waldschmidt et al¹⁸⁹ reported that, in contrast to equine skeletal muscle tissue cells, equine AMs responded efficiently to TLR2, 3 and 4 ligands. Furthermore, AMs show high expression of the specific macrophage markers CD14, CD163, TLR2, TLR3 and TLR4, have high phagocytic activity and are activated when stimulated with various proinflammatory ligands, thus supporting the importance of the local microenvironment in the activation status of the macrophage.²⁰ TLR9, the receptor that recognises unmethylated CpG oligodeoxynucleotide DNA,¹⁹⁰ is expressed by equine lung cells, including interstitial and AMs, with its expression also being upregulated by LPS stimulation.¹⁹¹ Similarly, TLR9 is expressed in mouse and human lung macrophages; its expression is also being enhanced by LPS.^{192,193}

Whereas normal mouse and human lungs have no PIMs, they are detected in the capillary endothelium of horses and other species,

such as cattle, pig and sheep, and are recognised as a member of the MPS.^{150,160,194,195} Equine PIMs are considered proinflammatory cells that play a critical role in equine lung inflammation, since they secrete the proinflammatory cytokines, TNF and IL-1B, and phagocytose in response to LPS.¹⁹⁶ Depletion of equine PIMs by gadolinium chloride resulted in a decreased severity of LPS-induced lung inflammation, reflected in a reduced mean pulmonary arterial pressure and lower IL-1B production in PIM-depleted horses compared to controls.¹⁹⁶ Furthermore, depletion of PIMs in horses affected with SEA resulted in a reduction in both clinical symptoms and lung inflammation, characterised by a reduced airway neutrophil count and a decrease in *IL8* and *TLR4* mRNA detected in airway-derived cells.¹⁹⁷ Equine PIMs have been shown to express TLR4 and TLR9, and the expression of TLR2, TLR4 and TLR9 in horse lungs was augmented after LPS treatment.^{185,191} As PIMs are capable of directly responding to inflammatory stimuli within both the airway and intravascular compartments, they have a unique role in pulmonary immunity, perhaps explaining the recognised susceptibility of the horse to endotoxaemia.¹⁵⁰ Recently, Harrison et al¹⁹⁸ reported an increased expression of inflammatory molecules, such as TLR4 and TLR9, in mononuclear cells in the lungs of septic foals, potentially including PIMs (see Figure 3). This group also reported an increase in PIMs from foals that died from sepsis, compared to healthy animals. Although PIMs are not observed in healthy humans, there is evidence of their existence in patients with liver disorders.¹⁹⁹⁻²⁰²

4 | THE HORSE AS AN ANIMAL MODEL FOR HUMAN DISEASE RESEARCH

The mouse is the most widely used animal model for studying human disease; however, many differences exist between mice and humans.^{13,203-205} As well as the obvious environmental, anatomical, pathophysiological and genetic differences, there are many distinctions in their innate immune responses,^{12,60,203,204,206} with specific relevance to mechanistic differences in common inflammatory conditions, such as trauma, burns or endotoxaemia.¹³ One such difference between rodents, humans and horses is their sensitivity to LPS, with horses and humans both having a relatively greater sensitivity than rodents. The estimated lethal dose of LPS in humans is thought to be approximately 0.015-0.03 µg/kg^{207,208} and 50-200 µg/kg in the horse.²⁰⁹ In contrast, the LD50 dose in the mouse is 25.6 mg/kg.²¹⁰ Despite the clear differences between horses and humans with respect to LPS lethal dose, the fact that this difference is significantly less than that between mice and humans suggests that the horse may be a comparably more appropriate model to study the response to LPS in humans. Horses, like other daylight-active animals including humans and pigs, have evolved differently to nocturnal animals, such as the mouse. Comparisons between the LPS-induced gene expression of equine AMs and BMDMs and that of other species have revealed significant similarities with human-derived cells and significant differences with murine-derived cells, further supporting the potential suitability of the horse as a model of human

innate immune responses, both systemically and at the level of the lung.²⁰⁻²² Further investigation of these interspecies similarities is clearly warranted; for example, via Cap analysis gene expression or RNA-seq. Findings derived from such studies could provide further insights into the inherently high level of sensitivity to LPS shared by both humans and horses. In turn, this may facilitate the identification of novel therapeutic targets for both endotoxaemia and sepsis in man, an objective which has been met with limited success via the use of rodent models. Similar studies have already been performed in other large animal models such as pig and sheep.^{60,61,211}

The Lipid A component of LPS is detected by macrophages via the PRR, TLR4, and the co-receptors, CD14 and MD2. The Lipid A component of LPS varies in structure between different bacterial species. This results in a variation in TLR4-mediated host responses.²¹² These variations in Lipid A structure also result in interspecies differences in ligand recognition. For example, the Lipid A from *Salmonella enterica* serovar *Typhimurium* is an agonist in all species studied. The Lipid IVa structure of *Escherichia coli* is a partial agonist in horses,²¹³ whereas in humans it is a full antagonist,²¹⁴ and a full agonist in mice.²¹⁵ Similarly, differences in *Rhodobacter sphaeroides* Lipid A recognition also exist between mice, humans and the horse.²¹⁶ Likewise, there are species differences in the recognition of lipopeptides by the PRRs TLR1 and TLR2.²¹⁷ TLR2 recognises bacterial antigens by forming heterodimers with TLR1 or TLR6 in both humans and horses. Although the response of TLR2/1 to the synthetic bacterial lipopeptides Pam2CSK4 and Pam3CSK4 is different between horse and human, the recognition of Pam2CSK4 by TLR2/6 is analogous between these species.²¹⁷ Walsh et al²¹³ found sequence differences in the MD2-TLR4 complex between species. A consequence of these differences was variation in the local charge distribution on the MD2-TLR4 complex. This suggests that the ability of Lipid IVa recognition, and subsequent signal transduction, is governed by electrostatic forces, with only partial contact between the ligand and MD2-TLR4 complex potentially resulting in reduced signalling; such a phenomenon may explain the interspecies differences in response to Lipid IVa.

Nitric oxide, a product of inducible NO synthase, is a major effector secreted by activated macrophages in rodents; however, it is not produced by human or porcine macrophages.^{21,60,203} Instead, LPS-stimulated human and porcine macrophages metabolise tryptophan through the induction of indoleamine dioxygenase (encoded by the *IDO* gene), kynurenine hydroxylase and kynureninase; in contrast, mouse macrophages do not use this pathway.^{60,218,219} Among ruminant species, cattle and water buffalo macrophages produce detectable NO and inducible *NOS2* mRNA, whereas sheep and goat macrophages do not.²¹ This difference was associated with insertions of an LPS-responsive mobile genetic element in the *NOS2* promoter. While Hammond et al²²⁰ reported an increase in *NOS2* mRNA in equine AMs after LPS challenge, with the consequent proposal that the *NOS2* enzyme might be a therapeutic target; others have failed to replicate this finding.²²¹ Equine alveolar and BMDMs did not produce detectable NO, nor express *NOS2* mRNA or other transcripts required for NO production in response to LPS.^{20,21} This

TABLE 1 Comparisons of horse and mouse models for human diseases

Comments		Horse	Mouse	References
General	Body, organ, litter size, longevity	Closer to human	Less similar	93,245
	Breeding costs	High	Low	
	Sample population, possible experiment repetition	Small	Big	
	Availability of immunological tools/reagents	Limited	High	
Genetic	Genetic diversity	High	Low	244,251-253
	Homology of protein coded genes with human	High	Low	
	Human CD16 is replicated	Replicated	Not replicated	
	Synteny with human	High	Low	
	Chromosome conservation with human	High	Low	
	Genome annotation	Poor	High	
Macrophage Biology	CD14 ⁺ CD16 ⁺ monocytes observed in humans	Detected	Not detected	14-21
	NO production in macrophages in response to LPS	Similar	Less similar	
	Response to LPS	Similar	Less Similar	21,22
Diseases	>100 hereditary conditions served as models for humans	Yes	No	1-3,6,7,9,10,74,265-268
	Musculoskeletal disorders-osteoarthritis	Common	Less common	
	Human endotoxaemia-sepsis pathophysiology	Similar	Less similar	
	Asthma—chronic obstructive pulmonary disease pathophysiology	Similar	Less similar	
	Human exercise pathophysiology/immunology	Similar	Less similar	
	Human infectious diseases	Similar	Less similar	
	Human mental and behavioural disorders	Similar	Less similar	
	Human metabolic diseases	Similar	Less similar	
Therapeutic strategies	Translational application to humans	Possible	Less possible	6,10,269,270

difference between species is associated with promoter evolution. There is clear conservation between the human and horse promoters and the poor alignment of the promoter sequences between mouse/horse and mouse/human.^{20,21} Finally, the comparative analysis of LPS-induced global gene expression of equine AMs with that of other species revealed significant similarities with human-derived AMs and significant differences with murine-derived cells, supporting the potential suitability of the horse as a model of human lung inflammation and endotoxaemia.²²

The full clinical significance of these differences is not yet fully understood; nonetheless, there is clear evidence of interspecies variation in innate immunity. Such differences likely influence the relative magnitude of the response of horses to LPS, or indeed other pathogen-associated and damage-associated molecular patterns. Such interspecies differences have resulted in an ever increasing demand for novel animal models (eg pig) in the study

of various human diseases; namely those which more closely resemble human pathophysiology, compared with rodents.^{187,222,223} In comparison to rodent models, the use of horses as appropriate models for the generation of data applicable to human disease research has clear practical, financial (eg feeding, housing and handling) and genetic limitations. However, there are also significant advantages of this approach, as proposed by other authors (summarised in Table 1).^{2,6,10,224,225}

Horses are animals with a high monetary value, and which require considerable investment from their owners. This is particularly true of equine athletes, whereby morbidity of any kind can result in substantial financial losses. Horses can suffer from an extensive range of infectious and inflammatory diseases, some of which are zoonotic, others of which share certain clinical and pathological features with equivalent human diseases.²²⁶⁻²²⁸ For example, POI is a life-threatening complication in horses,¹³¹ but is also a significant clinical issue

in humans. Furthermore, racehorses resemble elite human athletes and can suffer similar consequences in terms of repetitive injuries and exercise-associated pathology, including arthritis and respiratory tract infections. For example, racehorses commonly develop neutrophilic airway inflammation (MMEA) during the early phase of training.^{173,174} MMEA significantly impairs athletic performance¹⁷¹ and has a clear association with entry into training, with a reduction in prevalence as training progresses.^{229,230} Although entry into race training may result in increased airborne exposures to infectious and noninfectious agents, it is also associated with a significant increase in exercise intensity and frequency. The well-recognised association between high intensity exercise and symptoms of respiratory infection among human athletes has fuelled interest in the impact of training on immune function. This phenomenon, known as the 'open window' theory, reflects a temporal association between intense exercise and increased susceptibility to opportunistic infection.^{231,232} Despite localisation of inflammation to the airways in MMEA,¹⁷¹ few studies have assessed the influence of training on immune cell function specifically at this anatomical site, a key consideration in light of the previously mentioned disassociation between the response of equine monocytes and AMs to training.^{178,180}

As with many domesticated animals, selective breeding of horses has produced an array of breeds with specific traits relating to appearance (size and colour), temperament and performance (speed, strength and gait), resulting in more than 450 different breeds with a significant degree of diversity.^{233,234} Given the nature of line-breeding, each breed is likely to harbour breed-associated naturally occurring mutations, which may be associated with enhanced susceptibility or resistance to various diseases, many of which share characteristic features with specific diseases in humans. In light of these potential commonalities, the use of technologies, such as next-generation sequencing and genome-wide association studies, could facilitate the detection of quantitative trait loci or even specific genes involved in disease susceptibility. Furthermore, there are potential benefits of using genetic studies in horses in order to study human diseases. Indeed, more than 130 equine hereditary traits relating to specific equine diseases and disorders have already been suggested as valuable models for the study of human equivalents,²³⁵ (OMIA: <https://omia.org/home/>).

Genetic predisposition to equine respiratory tract diseases has recently been reviewed by Gerber et al.²³⁶ In this respect, SEA (syn. recurrent airway obstruction), a common equine respiratory disorder and a recognised model for human asthma, dominates the field of interest with certain chromosomal regions having already been linked to SEA and several candidate interleukin genes having been detected in these regions.^{237,238} *IL4RA*, a polymorphic gene involved in the Th2 response, has been recognised as a major candidate gene related to both human asthma and SEA susceptibility.²³⁹ Nonetheless, a few contradictory results have already been published regarding the role of this gene, suggesting loci heterogeneity for such conditions and highlighting the dual effect of genetic background and environmental factors on their development.^{237,239,240} These findings reflect the complex pathogenesis and pathogenetic

heterogeneity of both the human and equine forms of asthma, that in many cases has been characterised by a mixed as well as a polarised T helper cell immune response.²⁴¹⁻²⁴³

Many genes involved in immune function have a greater level of similarity between human and horse, than between human and mouse.²⁴⁴⁻²⁴⁶ Milenkovic et al²⁴⁴ identified 113 conserved segments between the equine and human genome. For example, *IL2* showed 72% identity with human and both *IL23* and *IL17* showed greater nucleotide sequence identity with human (89% and 84% respectively) than mouse (77% and 75% respectively).²⁴⁶ Similarly, equine IFN- γ -induced chemokine *CXCL9* has 86% homology with human, but only 74% with the mouse.²⁴⁷ Moreover, it is evidenced that CD14 as well as TLRs 2-5 and 9 are highly conserved between human and horse (Figure 5). With specific relevance to macrophages, equine *CSF1R* is similar to human *CSF1R*, containing 21 exons which code a 968 amino acid protein within a 30 kb region.²⁴⁸⁻²⁵⁰ Steinbach et al²⁴⁵ reported on the capacity for equine CSF2 to induce proliferation of a human TF-1 cell line and also demonstrated cross-reactivity of antihuman CD14, CD163 and CD206 monoclonal antibodies against horse PBMC. Furthermore, the myeloid differentiation marker ADGRE1 (F4/80) has recently been shown to be expressed by equine BMMs.⁶²

Chowdhary et al²⁵¹ were the first to study the radiation hybrid map of the horse genome and found the level of human-horse synteny to be greater than the level of mouse-horse synteny. While approximately half the number of horse chromosomes showed conserved synteny to one human chromosome;²³⁵ gene homology is still highly conserved between species.²⁵²⁻²⁵⁴ For example, Raudsepp et al found that the majority of equine chromosomes show homology to human chromosomes; the same group later demonstrated high conservation of gene order between horse and human chromosome X. These findings increase the likelihood that discoveries derived from the horse will have direct benefits for both equine and human health.

5 | CONCLUSIONS AND FUTURE PERSPECTIVES

In agreement with data derived from other species, the observations on the equine MPS summarised in this review refute the concept that 'a macrophage is a macrophage', highlighting the importance of studying cells derived from the specific tissue of interest. Recent global analyses on macrophages derived from mouse, human, pig, sheep and water buffalo have confirmed that tissue macrophages from different anatomical locations differ radically in their gene expression profiles;^{61,211,255-257} currently, there are a limited number of transcriptomic studies highlighting tissue differences in the horse. Graham and co-workers initiated the investigation of the horse transcriptome using human microarrays on equine brain and liver tissues and articular chondrocytes.²⁵⁸ Other studies using microarrays^{22,259} and RNA-seq²⁶⁰ investigated the equine transcriptome of various tissues. Although generally not designed to specifically assess the level of tissue macrophage differentiation, extraction and analysis of




FIGURE 5 Conservation and divergence of immune genes of the horse—comparison with humans and rodents. Phylogram trees of the innate immune response genes *CD14* (A), *TLR2* (B), *TLR3* (C), *TLR4* (D), *TLR5* (E) and *TLR9* (F) of rat, mouse, human and horse. Sequences were obtained from www.ensembl.org (Release 100).²⁷¹ Analysis was generated by Clustal Omega²⁷² and FigTree v1.4.4 (<http://tree.bio.ed.ac.uk/software/figtree/>). Each gene sequence is presented by species' official gene name and Ensembl gene ID

data derived from these studies clearly demonstrated tissue-specific expression profiles which correlate with specialised tissue functions. Further expansion of this work is warranted, including the genomic, phenotypic and functional characterisation of enzymatically dissociated macrophage populations derived from different tissues (eg brain [microglia], liver [Kupffer cells], spleen (*already isolated in our lab*) and GIT). Furthermore, the relatively recent development of equine tissue banks, such as the Equine Respiratory Tissue bank, University of Montreal (http://www.btre.ca/media/html/en_biobank.html) and

the extensive Thoroughbred-derived biobank described by Burns and Roberts (2018), should greatly facilitate the generation of data with cross-species translational potential.

Despite extensive research on equine inflammatory diseases, specific information on the equine MPS is lacking, largely due to the limited availability of appropriate molecular reagents. Consequently, many previous studies have relied on the successful use of cross-reactive human reagents.^{93,245} With the development of genomic/transcriptomic resources for the horse²³⁴ and emerging data from

numerous other large mammals (human, pig, cattle, sheep and water buffalo), it is now increasingly possible to address what is known, and what is not known, about the innate immune system of the horse in comparison to other species. The equine reference genome, EquCab2, from the Thoroughbred mare *Twilight* was first released in 2007 and advances in genomic technologies led to a new assembly of the reference genome, EquCab3, in 2018 using long-range sequencing data to improve contiguity.²⁶¹ While the equine reference genome has led to developments in equine genomics,²³⁵ equine genomic annotation still remains challenging^{234,262,263} and a high-resolution atlas of equine gene expression would substantially improve future efforts in this field.

Justification for the proposal of the horse as an appropriate animal model for human macrophage biology would necessitate the global analysis of gene expression across multiple tissues in this species. The need for defining the tissue-specific gene expression, regulation and functional annotation across domestic animal species has already been acknowledged by the establishment of the International FAANG project.²⁶⁴ The completion of the equine genome annotation would provide a major tool for future transcriptomic horse studies, the findings of which could selectively be applied to humans.

Together, in addition to the important similarities in both pathophysiology and macrophage/monocyte biology between horses and humans, the horse consists a great source of large volumes of different kind of samples that could be used for future studies. The volume of equine samples and the associated cell retrieval rates represent at least 2-3 orders of magnitude greater than those obtained from rodent models. Thus, for all these reasons highlighted above, we believe that greater consideration should be given to the horse as an appropriate candidate model for human disease.

ACKNOWLEDGEMENTS

We thank the Horserace Betting Levy Board for funding A.E. Karagianni's postdoctoral fellowship. Figures 1 to 4 were created by Biorender.com.

CONFLICT OF INTEREST

No competing interests have been declared.

AUTHOR CONTRIBUTIONS

All authors helped in the manuscript preparation and commented on the manuscript. The authors approved the final version of the manuscript.

ETHICAL ANIMAL RESEARCH

Not applicable to this review manuscript.

OWNER INFORMED CONSENT

Not applicable.

PEER REVIEW

The peer review history for this article is available at <https://publons.com/publon/10.1111/evj.13341>.

DATA ACCESSIBILITY STATEMENT

Not applicable.

ORCID

Anna E. Karagianni  <https://orcid.org/0000-0001-7684-2587>
Zofia M. Lisowski  <https://orcid.org/0000-0002-1323-9593>

REFERENCES

- Hodavance MS, Ralston SL, Pelczer I. Beyond blood sugar: the potential of NMR-based metabolomics for type 2 human diabetes, and the horse as a possible model. *Anal Bioanal Chem.* 2007;387:533-7.
- Turlej RK, Fievez L, Sandersen CF, Dogne S, Kirschvink N, Lekeux P, et al. Enhanced survival of lung granulocytes in an animal model of asthma: evidence for a role of GM-CSF activated STAT5 signaling pathway. *Thorax.* 2001;56:696-702.
- Koch TG, Betts DH. Stem cell therapy for joint problems using the horse as a clinically relevant animal model. *Expert Opin Biol Ther.* 2007;7(11):1621-6.
- Seltenhammer MH, Heere-Ress E, Brandt S, Druml T, Jansen B, Pehamberger H, et al. Comparative histopathology of grey-horse-melanoma and human malignant melanoma. *Pigment Cell Res.* 2004;17:674-81.
- Deeg CA, Altmann F, Hauck SM, Schoeffmann S, Amann B, Stangassinger M, et al. Down-regulation of pigment epithelium-derived factor in uveitic lesion associates with focal vascular endothelial growth factor expression and breakdown of the blood-retinal barrier. *Proteomics.* 2007;7:1540-8.
- Bullone M, Lavoie JP. Asthma "of horses and men"-how can equine heaves help us better understand human asthma immunopathology and its functional consequences? *Mol. Immunol.* 2015;66:97-105.
- Nicholas, FW. Online Mendelian Inheritance in Animals (OMIA): a comparative knowledgebase of genetic disorders and other familial traits in non-laboratory animals. *Nucleic Acids Res.* 2003;31(1):275-7.
- Carnevale EM. The mare model for follicular maturation and reproductive aging in the woman. *Theriogenology.* 2008;69:23-30.
- Fureix C, Jégo P, Henry S, Lansade L, Hausberger M. Towards an ethological animal model of depression? A study on horses. *PLoS One.* 2012;7(6):e39280.
- Danek M, Danek J, Araszkiwicz A. Large animals as potential models of human mental and behavioral disorders. *Psychiatr Pol.* 2017;51:1009-27.
- Hume DA. The many alternative faces of macrophage activation. *Front Immunol.* 2015;6:370.
- Schroder K, Irvine KM, Taylor MS, Bokil NJ, Cao K-AL, Masterman K-A, et al. Conservation and divergence in Toll-like receptor 4-regulated gene expression in primary human versus mouse macrophages. *Proc Natl Acad Sci USA.* 2012;109:E944-E953.
- Junhee S, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Weihong X, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. *Proc Natl Acad Sci USA.* 2013;110:3507-12.
- Fingerle G, Pforte A, Passlick B, Blumenstein M, Strobel M, Zieglerheitbrock HWL. The novel subset of CD14+/CD16+ blood monocytes is expanded in sepsis patients. *Blood.* 1993;82:3170-6.
- Sunderkotter C, Nikolic T, Dillon MJ, van Rooijen N, Stehling M, Drevets DA, et al. Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response. *J Immunol.* 2004;172:4410-7.
- Noronha LE, Harman RM, Wagner B, Antczak DF. Generation and characterization of monoclonal antibodies to equine CD16. *Vet Immunol Immunopathol.* 2012;146:135-42.

17. Hawkins DL, MacKay RJ, MacKay SLD, Moldawer LL. Human interleukin 10 suppresses production of inflammatory mediators by LPS-stimulated equine peritoneal macrophages. *Vet Immunol Immunopathol.* 1998;66:1-10.
18. Weinberg JB, Misukonis MA, Shami PJ, Mason SN, Sauls DL, Dittman WA, et al. Human mononuclear phagocyte inducible nitric-oxide synthase (iNOS) - analysis of iNOS messenger-RNA, iNOS protein, biopterin, and nitric-oxide production by blood monocytes and peritoneal-macrophages. *Blood.* 1995;86:1184-95.
19. Ito H, Koide N, Morikawa A, Hassan F, Islam S, Tumurkhuu G, et al. Augmentation of lipopolysaccharide-induced nitric oxide production by alpha-galactosylceramide in mouse peritoneal cells. *J Endotoxin Res.* 2005;11:213-9.
20. Karagianni AE, Kapetanovic R, McGorum BC, Hume DA, Pirie SR. The equine alveolar macrophage: functional and phenotypic comparisons with peritoneal macrophages. *Vet Immunol Immunopathol.* 2013;155:219-28.
21. Young R, Bush SJ, Lefevre L, McCulloch MEB, Lisowski ZM, Muriuki C, et al. Species-specific transcriptional regulation of genes involved in nitric oxide production and arginine metabolism in macrophages. *ImmunoHorizons.* 2018;2:27-37.
22. Karagianni AE, Kapetanovic R, Summers KM, McGorum BC, Hume DA, Pirie RS. Comparative transcriptome analysis of equine alveolar macrophages. *Equine Vet J.* 2016;49:375-82.
23. Hume DA, Ross IL, Himes SR, Sasmono RT, Wells CA, Ravasi T. The mononuclear phagocyte system revisited. *J Leukoc Biol.* 2002;72:621-7.
24. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. *Nat Rev Immunol.* 2005;5:953-64.
25. Hume DA. Differentiation and heterogeneity in the mononuclear phagocyte system. *Mucosal Immunol.* 2008;1:432-41.
26. van Furth R, Cohn ZA. The origin and kinetics of mononuclear phagocytes. *J Exp Med.* 1968;128:415-35.
27. van Furth R, Cohn ZA, Hirsch JG, Humphrey JH, Spector WG, Langevoort HL. The mononuclear phagocyte system: a new classification of macrophages, monocytes, and their precursor cells. *Bull World Health Organ.* 1972;46:845-52.
28. Ginhoux F, Guilliams M. Tissue-resident macrophage ontogeny and homeostasis. *Immunity.* 2016;44:439-49.
29. Hume DA, Irvine KM, Pridans C. The mononuclear phagocyte system: the relationship between monocytes and macrophages. *Trends Immunol.* 2019;40:98-112.
30. Gomez Perdiguero E, Klapproth K, Schulz C, Busch K, Azzoni E, Crozet L, et al. Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors. *Nature.* 2015;518:547-51.
31. Hoeffel G, Ginhoux F. Fetal monocytes and the origins of tissue-resident macrophages. *Cell Immunol.* 2018;330:5-15.
32. Hashimoto D, Chow A, Noizat C, Teo P, Beasley MB, Leboeuf M, et al. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. *Immunity.* 2013;38:792-804.
33. Schulz C, Perdiguero EG, Chorro L, Szabo-Rogers H, Cagnard N, Kierdorf K, et al. A Lineage of myeloid cells independent of Myb and hematopoietic stem cells. *Science.* 2012;336:86-90.
34. Yona S, Kim K-W, Wolf Y, Mildner A, Varol D, Breker M, et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. *Immunity.* 2013;38:79-91.
35. De Schepper S, Verheijden S, Aguilera-Lizarraga J, Viola MF, Boesmans W, Stakenborg N, et al. Self-maintaining gut macrophages are essential for intestinal homeostasis. *Cell.* 2019;176:676.
36. Hambleton S, Salem S, Bustamante J, Bigley V, Boisson-Dupuis S, Azevedo J, et al. IRF8 mutations and human dendritic-cell immunodeficiency. *N Engl J Med.* 2011;365:127-38.
37. Jenkins SJ, Hume DA. Homeostasis in the mononuclear phagocyte system. *Trends Immunol.* 2014;35:358-67.
38. Prinz M, Jung S, Priller J. Microglia biology: one century of evolving concepts. *Cell.* 2019;179:292-311.
39. Li W, Wang Y, Zhao H, Zhang H, Xu Y, Wang S, et al. Identification and transcriptome analysis of erythroblastic island macrophages. *Blood.* 2019;134:480-91.
40. Mass E, Ballesteros I, Farlik M, Halbritter F, Gunther P, Crozet L, et al. Specification of tissue-resident macrophages during organogenesis. *Science.* 2016;353(6304):aaf4238.
41. Summers KM, Hume DA. Identification of the macrophage-specific promoter signature in FANTOM5 mouse embryo developmental time course data. *J Leukoc Biol.* 2017;102:1081-92.
42. Bonnardel J, T'Jonck W, Gaublotte D, Browaeys R, Scott CL, Martens L, et al. Stellate cells, hepatocytes, and endothelial cells imprint the kupffer cell identity on monocytes colonizing the liver macrophage niche. *Immunity.* 2019;51(4):638-654.e9.
43. Sakai M, Troutman TD, Seidman JS, Ouyang Z, Spann NJ, Abe Y, et al. Liver-derived signals sequentially reprogram myeloid enhancers to initiate and maintain Kupffer cell identity. *Immunity.* 2019;51(4):655-670.e8.
44. Chakarov S, Lim HY, Tan L, Lim SY, See P, Lum J, et al. Two distinct interstitial macrophage populations coexist across tissues in specific subtissular niches. *Science.* 2019;363(6432):eaau0964.
45. Hume DA, Freeman TC. Transcriptomic analysis of mononuclear phagocyte differentiation and activation. *Immunol Rev.* 2014;262:74-84.
46. Schultze JL. Transcriptional programming of human macrophages: on the way to systems immunology. *J Mol Med.* 2015;93:589-97.
47. Locati M, Curtale G, Mantovani A. Diversity, mechanisms, and significance of macrophage plasticity. *Annu Rev Pathol.* 2019;15:123-47.
48. Hume DA, Caruso M, Ferrari-Cestari M, Summers KM, Pridans C, Irvine KM. Phenotypic impacts of CSF1R deficiencies in humans and model organisms. *J Leukoc Biol.* 2019;107:205-19.
49. Sirin NG, Oguz Akarsu E, Kocasoy Orhan E, Erbas B, Artug T, Dede HO, et al. Parameters derived from compound muscle action potential scan for discriminating amyotrophic lateral sclerosis-related denervation. *Muscle Nerve.* 2019;60:400-8.
50. Uchikawa S, Kawaoka T, Aikata H, Kodama K, Nishida Y, Inagaki Y, et al. Clinical outcomes of sorafenib treatment failure for advanced hepatocellular carcinoma and candidates for regorafenib treatment in real-world practice. *Hepatol Res.* 2018;48:814-20.
51. MacDonald KP, Palmer JS, Cronau S, Seppanen E, Olver S, Raffelt NC, et al. An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation. *Blood.* 2010;116:3955-63.
52. Gow DJ, Sauter KA, Pridans C, Moffat L, Sehgal A, Stutchfield BM, et al. Characterisation of a novel Fc conjugate of macrophage colony-stimulating factor. *Mol Ther.* 2014;22:1580-92.
53. Irvine KM, Caruso M, Cestari MF, Davis GM, Keshvari S, Sehgal A, et al. Analysis of the impact of CSF-1 administration in adult rats using a novel Csf1r-mApple reporter gene. *J Leukoc Biol.* 2019;107:221-35.
54. Sauter KA, Waddell LA, Lisowski ZM, Young R, Lefevre L, Davis GM, et al. Macrophage colony-stimulating factor (CSF1) controls monocyte production and maturation and the steady-state size of the liver in pigs. *Am J Physiol Gastrointest Liver Physiol.* 2016;311:G533-G547.
55. Sauter KA, Pridans C, Sehgal A, Bain CC, Scott C, Moffat L, et al. The MacBlue binary transgene (csf1r-gal4VP16/UAS-ECFP) provides a novel marker for visualisation of subsets of monocytes, macrophages and dendritic cells and responsiveness to CSF1 administration. *PLoS One.* 2014;9:e105429.

56. Williams M, De Kleer I, Henri S, Post S, Vanhoutte L, De Prijck S, et al. Alveolar macrophages develop from fetal monocytes that differentiate into long-lived cells in the first week of life via GM-CSF. *J Exp Med*. 2013;210:1977-92.
57. Hume DA, Gordon S. Optimal condition for proliferation of bone marrow-derived mouse macrophages in culture - the role of CSF-1, serum, CA-2+, and adherence. *J Cell Physiol*. 1983;117:189-94.
58. Corraliza IM, Soler G, Eichmann K, Modolell M. Arginase induction by suppressors of nitric-oxide synthesis (IL-4, IL-10 AND PGE(2)) in murine bone-marrow-derived macrophages. *Biochem Biophys Res Comm*. 1995;206:667-73.
59. Raza S, Robertson KA, Lacaze PA, Page D, Enright AJ, Ghazal P, et al. A logic-based diagram of signalling pathways central to macrophage activation. *BMC Syst Biol*. 2008;2(1):36.
60. Kapetanovic R, Fairbairn L, Beraldi D, Sester DP, Archibald AL, Tuggle CK, et al. Pig bone marrow-derived macrophages resemble human macrophages in their response to bacterial lipopolysaccharide. *J Immunol*. 2012;188:3382-94.
61. Clark EL, Bush SJ, McCulloch MEB, Farquhar IL, Young R, Lefevre L, et al. A high resolution atlas of gene expression in the domestic sheep (*Ovis aries*). *PLoS Genet*. 2017;13:e1006997.
62. Waddell LA, Lefevre L, Bush SJ, Raper A, Young R, Lisowski ZM, et al. ADGRE1 (EMR1, F4/80) is a rapidly-evolving gene expressed in mammalian monocyte-macrophages. *Front Immunol*. 2018;9:2246.
63. Watson ED, Mair TS, Sweeney CR. Immunoreactive prostaglandin production by equine monocytes and alveolar macrophages and concentrations of PGE2 and PGF in bronchoalveolar lavage fluid. *Res Vet Sci*. 1990;49:88-91.
64. Raabe MR, Issel CJ, Montelaro RC. Equine monocyte-derived macrophage cultures and their applications for infectivity and neutralization studies of equine infectious anemia virus. *J Virol Methods*. 1998;71:87-104.
65. Moore BD, Balasuriya UBR, Watson JL, Bosio CM, MacKay RJ, MacLachlan NJ. Virulent and avirulent strains of equine arteritis virus induce different quantities of TNF-alpha and other proinflammatory cytokines in alveolar and blood-derived equine macrophages. *Virology*. 2003;314:662-70.
66. Swardson CJ, Kociba GJ, Perryman LE. Effects of equine infectious-anemia virus on hematopoietic progenitors invitro. *Am J Vet Res*. 1992;53:1176-9.
67. Werners AH, Bull S, Fink-Gremmels J, Bryant CE. Generation and characterisation of an equine macrophage cell line (e-CAS cells) derived from equine bone marrow cells. *Vet Immunol Immunopathol*. 2004;97:65-76.
68. Lorsch JR, Collins FS, Lippincott-Schwartz J. Cell biology. Fixing problems with cell lines. *Science*. 2014;346:1452-3.
69. Oh HY, Jin X, Kim JG, Oh MJ, Pian X, Kim JM, et al. Characteristics of primary and immortalized fibroblast cells derived from the miniature and domestic pigs. *BMC Cell Biol*. 2007;8:20.
70. Evans E, Paillet R, Lopez-Alvarez MR. A comprehensive analysis of e-CAS cell line reveals they are mouse macrophages. *Sci Rep*. 2018;8:8237.
71. Barussi FC, Bastos FZ, Leite LM, Fragoso FY, Senegaglia AC, Brofman PR, et al. Intratracheal therapy with autologous bone marrow-derived mononuclear cells reduces airway inflammation in horses with recurrent airway obstruction. *Respir Physiol Neurobiol*. 2016;232:35-42.
72. Firinci F, Karaman M, Baran Y, Bagriyanik A, Ayyildiz ZA, Kiray M, et al. Mesenchymal stem cells ameliorate the histopathological changes in a murine model of chronic asthma. *Int Immunopharmacol*. 2011;11:1120-6.
73. May SA, Hooke RE, Lees P. The characterization of equine interleukin-1. *Vet Immunol Immunopathol*. 1990;24:169-75.
74. Morris DD. Endotoxemia in horses- a review of cellular and humoral mediators involved in its pathogenesis. *J Vet Intern Med*. 1991;5:167-81.
75. Cywes-Bentley C, Rocha JN, Bordin AI, Vinacur M, Rehman S, Zaidi TS, et al. Antibody to Poly-N-acetyl glucosamine provides protection against intracellular pathogens: mechanism of action and validation in horse foals challenged with *Rhodococcus equi*. *PLoS Pathog*. 2018;14:e1007160.
76. Cacciolatti C, Meyer-Ficca ML, Southwood LL, Meyer RG, Bertolotti L, Zaruco L. In vitro effects of poly(ADP-ribose) polymerase inhibitors on the production of tumor necrosis factor-alpha by interferon-gamma and lipopolysaccharide-stimulated peripheral blood mononuclear cells of horses. *Am J Vet Res*. 2019;80:663-9.
77. Saini S, Singha H, Siwach P, Tripathi BN. Recombinant horse interleukin-4 and interleukin-10 induced a mixed inflammatory cytokine response in horse peripheral blood mononuclear cells. *Vet World*. 2019;12:496-503.
78. Witonsky S, Buechner-Maxwell V, Santonastasto A, Pleasant R, Werre S, Wagner B, et al. Can levamisole upregulate the equine cell-mediated macrophage (M1) dendritic cell (DC1) T-helper 1 (CD4 Th1) T-cytotoxic (CD8) immune response in vitro? *J Vet Intern Med*. 2019;33:889-96.
79. Pacholewska A, Marti E, Leeb T, Jagannathan V, Gerber V. LPS-induced modules of co-expressed genes in equine peripheral blood mononuclear cells. *BMC Genom*. 2017;18:34.
80. Schnabel CL, Babasyan S, Freer H, Wagner B. CXCL10 production in equine monocytes is stimulated by interferon-gamma. *Vet Immunol Immunopathol*. 2019;207:25-30.
81. Cassano JM, Schnabel LV, Goodale MB, Fortier LA. The immunomodulatory function of equine MSCs is enhanced by priming through an inflammatory microenvironment or TLR3 ligand. *Vet Immunol Immunopathol*. 2018;195:33-9.
82. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. *Trends Immunol*. 2004;25:677-86.
83. Antonelli A, Ferrari SM, Giuggioli D, Ferrannini E, Ferri C, Fallahi P. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. *Autoimmun Rev*. 2014;13:272-80.
84. Grunig G, Hulliger C, Winder C, Hermann M, Jungi TW, Vonfellenberg R. Spontaneous and lipopolysaccharide-induced expression of procoagulant activity by equine lung macrophages in comparison with blood monocytes and blood neutrophils. *Vet Immunol Immunopathol*. 1991;29:295-312.
85. Kawai T, Takeuchi O, Fujita T, Inoue J-I, Mühlradt PF, Sato S, et al. Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. *J Immunol*. 2001;167:5887-94.
86. Kawai T, Akira S. TLR signaling. *Semin Immunol*. 2007;19(1):24-32.
87. Figueiredo MD, Vandenplas ML, Hurley DJ, Moore JN. Differential induction of MyD88-and TRIF-dependent pathways in equine monocytes by Toll-like receptor agonists. *Vet Immunol Immunopathol*. 2009;127:125-34.
88. Ahn H, Kim J, Lee H, Lee E, Lee GS. Characterization of equine inflammasomes and their regulation. *Vet Res Commun*. 2020;44(2):51-9.
89. Gombart AF. The vitamin D-antimicrobial peptide pathway and its role in protection against infection. *Future Microbiol*. 2009;4:1151-65.
90. Parkinson NJ, Buechner-Maxwell VA, Witonsky SG, Pleasant RS, Werre SR, Ahmed SA. Characterization of basal and lipopolysaccharide-induced microRNA expression in equine peripheral blood mononuclear cells using Next-Generation Sequencing. *PLoS One*. 2017;12:e0177664.
91. Kwon S, Vandenplas ML, Figueiredo MD, Salter CE, Andrietti AL, Robertson TP, et al. Differential induction of Toll-like receptor gene expression in equine monocytes activated by Toll-like receptor ligands or TNF-alpha. *Vet Immunol Immunopathol*. 2010;138:213-7.

92. Kwon S, Gewirtz AT, Hurley DJ, Robertson TP, Moore JN, Vandenplas ML. Disparities in TLR5 expression and responsiveness to flagellin in equine neutrophils and mononuclear phagocytes. *J Immunol.* 2011;186:6263–70.
93. Ibrahim S, Saunders K, Kydd JH, Lunn DP, Steinbach F. Screening of anti-human leukocyte monoclonal antibodies for reactivity with equine leukocytes. *Vet Immunol Immunopathol.* 2007;119:63–80.
94. Schnabel CL, Wemette M, Babasyan S, Freer H, Baldwin C, Wagner B. C-C motif chemokine ligand (CCL) production in equine peripheral blood mononuclear cells identified by newly generated monoclonal antibodies. *Vet Immunol Immunopathol.* 2018;204:28–39.
95. Williams M, Ginhoux F, Jakubzick C, Naik SH, Onai N, Schraml BU, et al. Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny. *Nat Rev Immunol.* 2014;14:571–8.
96. Hume DA. Macrophages as APC and the dendritic cell myth. *J Immunol.* 2008;181:5829–35.
97. Moyo NA, Marchi E, Steinbach F. Differentiation and activation of equine monocyte-derived dendritic cells are not correlated with CD206 or CD83 expression. *Immunology.* 2013;139:472–83.
98. Cavatorta DJ, Erb HN, Flaminio MJB. Ex vivo generation of mature equine monocyte-derived dendritic cells. *Vet Immunol Immunopathol.* 2009;131:259–67.
99. Ziegler A, Everett H, Hamza E, Garbani M, Gerber V, Marti E, et al. Equine dendritic cells generated with horse serum have enhanced functionality in comparison to dendritic cells generated with fetal bovine serum. *BMC Vet Res.* 2016;12:254.
100. Ziegler A, Marti E, Summerfield A, Baumann A. Identification and characterization of equine blood plasmacytoid dendritic cells. *Dev Comp Immunol.* 2016;65:352–7.
101. Lee Y, Kiupel M, Soboll Hussey G. Characterization of respiratory dendritic cells from equine lung tissues. *BMC Vet Res.* 2017;13:313.
102. Lopez BS, Hurley DJ, Giancola S, Giguere S, Felipe MJB, Hart KA. The effect of age on foal monocyte-derived dendritic cell (MoDC) maturation and function after exposure to killed bacteria. *Vet Immunol Immunopathol.* 2019;210:38–45.
103. Lee SH, Starkey PM, Gordon S. Quantitative analysis of total macrophage content in adult mouse tissues. *Immunochemical studies with monoclonal antibody F4/80.* *J Exp Med.* 1985;161:475–89.
104. Hume DA, Perry VH, Gordon S. The mononuclear phagocyte system of the mouse defined by immunohistochemical localisation of antigen F4/80: macrophages associated with epithelia. *Anat Rec.* 1984;210:503–12.
105. Bain CC, Schridde A. Origin, differentiation, and function of intestinal macrophages. *Front Immunol.* 2018;9:2733.
106. Kristek M, Collins LE, DeCoursey J, McEvoy FA, Loscher CE. Soluble factors from colonic epithelial cells contribute to gut homeostasis by modulating macrophage phenotype. *Innate Immun.* 2015;21:358–69.
107. Smith PD, Smythies LE, Mosteller-Barnum M, Sibley DA, Russell MW, Merger M, et al. Intestinal macrophages lack CD14 and CD89 and consequently are down-regulated for LPS- and IgA-mediated activities. *J Immunol.* 2001;167:2651–6.
108. Hausmann M, Kiessling S, Mestermann S, Webb G, Spottl T, Andus T, et al. Toll-like receptors 2 and 4 are up-regulated during intestinal inflammation. *Gastroenterology.* 2002;122:1987–2000.
109. Zigmund E, Bernshtein B, Friedlander G, Walker CR, Yona S, Kim KW, et al. Macrophage-restricted interleukin-10 receptor deficiency, but not IL-10 deficiency, causes severe spontaneous colitis. *Immunity.* 2014;40:720–33.
110. Ip WKE, Hoshi N, Shouval DS, Snapper S, Medzhitov R. Anti-inflammatory effect of IL-10 mediated by metabolic reprogramming of macrophages. *Science.* 2017;356:513–9.
111. Mikkelsen HB, Rumessen JJ. Characterization of macrophage-like cells in the external layers of human small and large intestine. *Cell Tissue Res.* 1992;270:273–9.
112. Mikkelsen HB, Garbarsch C, Tranum-Jensen J, Thuneberg L. Macrophages in the small intestinal muscularis externa of embryos, newborn and adult germ-free mice. *J Mol Histol.* 2004;35:377–87.
113. Kalff JC, Schwarz NT, Walgenbach KJ, Schraut WH, Bauer AJ. Leukocytes of the intestinal muscularis: their phenotype and isolation. *J Leukoc Biol.* 1998;63:683–91.
114. Eskandari MK, Kalff JC, Billiar TR, Lee KK, Bauer AJ. Lipopolysaccharide activates the muscularis macrophage network and suppresses circular smooth muscle activity. *Am J Physiol.* 1997;273:G727–G734.
115. Mikkelsen HB, Larsen JO, Hadberg H. The macrophage system in the intestinal muscularis externa during inflammation: an immunohistochemical and quantitative study of osteopetrotic mice. *Histochem Cell Biol.* 2008;130:363–73.
116. Muller PA, Kosco B, Rajani GM, Stevanovic K, Berres ML, Hashimoto D, et al. Crosstalk between muscularis macrophages and enteric neurons regulates gastrointestinal motility. *Cell.* 2014;158:1210.
117. Sehgal A, Donaldson DS, Pridans C, Sauter KA, Hume DA, Mabbott NA. The role of CSF1R-dependent macrophages in control of the intestinal stem-cell niche. *Nat Commun.* 2018;9:1272.
118. Bain CC, Bravo-Blas A, Scott CL, Perdiguer EG, Geissmann F, Henri S, et al. Constant replenishment from circulating monocytes maintains the macrophage pool in the intestine of adult mice. *Nat Immunol.* 2014;15:929–37.
119. Bujko A, Atlasy N, Landsverk OJB, Richter L, Yaqub S, Horneland R, et al. Transcriptional and functional profiling defines human small intestinal macrophage subsets. *J Exp Med.* 2018;215:441–58.
120. Farro G, Stakenborg M, Gomez-Pinilla PJ, Labeeuw E, Govers G, Di Giovangiulio M, et al. CCR2-dependent monocyte-derived macrophages resolve inflammation and restore gut motility in postoperative ileus. *Gut.* 2017;66:2098–109.
121. Grosche A, Morton AJ, Graham AS, Valentine JF, Abbott JR, Polyak MM, et al. Mucosal injury and inflammatory cells in response to brief ischaemia and reperfusion in the equine large colon. *Equine Vet J.* 2011;43:16–25.
122. Yamate J, Yoshida H, Tsukamoto Y, Ide M, Kuwamura M, Ohashi F, et al. Distribution of cells immunopositive for AM-3K, a novel monoclonal antibody recognizing human macrophages, in normal and diseased tissues of dogs, cats, horses, cattle, pigs, and rabbits. *Vet Pathol.* 2000;37:168–76.
123. Lisowski ZM, Sauter KA, Waddell LA, Hume DA, Pirie S, Hudson NPH. Immunohistochemical study of morphology and distribution of CD163+ve macrophages in the normal adult equine gastrointestinal tract. *Vet Immunol Immunopathol.* 2020. <https://doi.org/10.1016/j.vetimm.2020.110073>. in press
124. Steuer AE, Loynachan AT, Nielsen MK. Evaluation of the mucosal inflammatory responses to equine cyathostomins in response to anthelmintic treatment. *Vet Immunol Immunopathol.* 2018;199:1–7.
125. Packer M, Patterson-Kane JC, Smith KC, Durham AE. Quantification of immune cell populations in the lamina propria of equine jejunal biopsy specimens. *J Comp Pathol.* 2005;132:90–5.
126. Kalff JC, Carlos TM, Schraut WH, Billiar TR, Simmons RL, Bauer AJ. Surgically induced leukocytic infiltrates within the rat intestinal muscularis mediate postoperative ileus. *Gastroenterology.* 1999;117:378–87.
127. Kalff JC, Turler A, Schwarz NT, Schraut WH, Lee KK, Twardy DJ, et al. Intra-abdominal activation of a local inflammatory response within the human muscularis externa during laparotomy. *Ann Surg.* 2003;237:301–15.
128. Kühl AA, Erben U, Kredel LI, Siegmund B. Diversity of intestinal macrophages in inflammatory bowel diseases. *Front Immunol.* 2015;6:613.

129. Jones GR, Bain CC, Fenton TM, Kelly A, Brown SL, Ivens AC, et al. Dynamics of colon monocyte and macrophage activation during colitis. *Front Immunol.* 2018;9:2764.
130. Schumacher J, Edwards JF, Cohen ND. Chronic idiopathic inflammatory bowel diseases of the horse. *J Vet Intern Med.* 2000;14:258–65.
131. Lisowski ZM, Pirie RS, Blikslager AT, Lefebvre D, Hume DA, Hudson NPH. An update on equine post-operative ileus: definitions, pathophysiology and management. *Equine Vet J.* 2018;50:292–303.
132. Little D, Tomlinson JE, Blikslager AT. Post operative neutrophilic inflammation in equine small intestine after manipulation and ischaemia. *Equine Vet J.* 2005;37:329–35.
133. Isidro RA, Appleyard CB. Colonic macrophage polarization in homeostasis, inflammation, and cancer. *Am J Physiol Gastrointest Liver Physiol.* 2016;311:G59–G73.
134. Franze E, Caruso R, Stolfi C, Sarra M, Cupi ML, Caprioli F, et al. Lesional accumulation of CD163-expressing cells in the gut of patients with inflammatory bowel disease. *PLoS One.* 2013;8:e69839.
135. Buechler C, Ritter M, Orsó E, Langmann T, Klucken J, Schmitz G. Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro- and antiinflammatory stimuli. *J Leukoc Biol.* 2000;67:97–103.
136. Nomura F, Akashi S, Sakao Y, Sato S, Kawai T, Matsumoto M, et al. Cutting edge: Endotoxin tolerance in mouse peritoneal macrophages correlates with down-regulation of surface Toll-like receptor 4 expression. *J Immunol.* 2000;164:3476–9.
137. Okabe Y, Medzhitov R. Tissue-specific signals control reversible program of localization and functional polarization of macrophages. *Cell.* 2014;157:832–44.
138. Rosas M, Davies LC, Giles PJ, Liao CT, Kharfan B, Stone TC, et al. The transcription factor Gata6 links tissue macrophage phenotype and proliferative renewal. *Science.* 2014;344:645–8.
139. Halme J. Release of tumor necrosis factor-alpha by human peritoneal-macrophages *in vivo* and *in vitro*. *Am J Obstet Gynecol.* 1989;161:1718–25.
140. Paul PS, Mengeling WL, Brown TT. Replication of porcine parvovirus in peripheral-blood lymphocytes, monocytes, and peritoneal-macrophages. *Infect Immun.* 1979;25:1003–7.
141. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, et al. A human gut microbial gene catalogue established by metagenomic sequencing. *Nature.* 2010;464(7285):59–65.
142. Irvine KM, Banh X, Gadd VL, Wojcik KK, Ariffin JK, Jose S, et al. CR1g-expressing peritoneal macrophages are associated with disease severity in patients with cirrhosis and ascites. *JCI Insight.* 2016;1:e86914.
143. Irvine KM, Ratnasekera I, Powell EE, Hume DA. Causes and consequences of innate immune dysfunction in cirrhosis. *Front Immunol.* 2019;10:293.
144. Alonso JM, Peccinini RG, Campos ML, Nitta TY, Akutagawa TYM, Crescencio AP, et al. Plasma and peritoneal fluid concentrations of ceftriaxone after intravenous and intraperitoneal administration in horses. *Vet J.* 2018;234:72–6.
145. Morris DD, Moore JN. Endotoxin-induced production of thromboxane and prostacyclin by equine peritoneal macrophages. *Circ Shock.* 1987;23:295–303.
146. Morris DD, Moore JN, Fischer K, Tarleton RL. Endotoxin-induced tumor-necrosis-factor activity production by equine peritoneal macrophages. *Circ Shock.* 1990;30:229–36.
147. Morris DD, Crowe N, Moore JN, Moldawer LL. Endotoxin-induced production of interleukin-6 by equine peritoneal-macrophages *in vitro*. *Am J Vet Res.* 1992;53:1298–301.
148. Morris DD, Moore JN, Crowe N, Fischer JK. Dexamethasone reduces endotoxin-induced tumor-necrosis-factor activity production *in vitro* by equine peritoneal-macrophages. *Cornell Vet.* 1991;81:267–76.
149. Barton MH, Collatos C, Moore JN. Endotoxin induced expression of tumour necrosis factor, tissue factor and plasminogen activator inhibitor activity by peritoneal macrophages. *Equine Vet J.* 1996;28:382–9.
150. Schneberger D, Aharonson-Raz K, Singh B. Pulmonary intravascular macrophages and lung health: what are we missing? *Am J Physiol Lung Cell Mol Physiol.* 2012;302:L498–L503.
151. Laskin DL, Weinberger B, Laskin JD. Functional heterogeneity in liver and lung macrophages. *J Leukoc Biol.* 2001;70:163–70.
152. Bilyk N, Holt PG. The surface phenotypic characterization of lung macrophages in C3H/HEJ mice. *Immunology.* 1991;74:645–51.
153. Nibbering PH, Leijh PCJ, Vanfurth R. Quantitative immunocytochemical characterization of mononuclear phagocytes.1. Monoblasts, promonocytes, monocytes and peritoneal and alveolar macrophages. *Cell Immunol.* 1987;105:374–85.
154. Cai Y, Sugimoto C, Arainga M, Alvarez X, Didier ES, Kuroda MJ. *In vivo* characterization of alveolar and interstitial lung macrophages in rhesus macaques: implications for understanding lung disease in humans. *J Immunol.* 2014;15:2821–9.
155. Bilyk N, Mackenzie JS, Papadimitriou JM, Holt PG. Functional studies on macrophage populations in the airways and the lung wall of SPF mice in the steady-state and during respiratory virus-infection. *Immunology.* 1988;65:417–25.
156. Gibbins SL, Thomas SM, Atif SM, McCubbrey AL, Desch AN, Danhorn T, et al. Three unique interstitial macrophages in the murine lung at steady state. *Am J Respir Cell Mol Biol.* 2017;57:66–76.
157. Kapetanovic R, Fairbairn L, Downing A, Beraldi D, Sester DP, Freeman TC, et al. The impact of breed and tissue compartment on the response of pig macrophages to lipopolysaccharide. *BMC Genom.* 2013;14:581–96.
158. van de Laar L, Saelens W, De Prijck S, Martens L, Scott CL, Van Isterdael G, et al. Yolk sac macrophages, fetal liver, and adult monocytes can colonize an empty niche and develop into functional tissue-resident macrophages. *Immunity.* 2016;44:755–68.
159. Laan TTJM, Bull S, Pirie R, Fink-Gremmels J. The role of alveolar macrophages in the pathogenesis of recurrent airway obstruction in horses. *J Vet Intern Med.* 2006;20:167–74.
160. Aharonson-Raz K, Singh B. Pulmonary intravascular macrophages and endotoxin-induced pulmonary pathophysiology in horses. *Can J Vet Res.* 2010;74:45–9.
161. Baggolini M. Interleukin-8 - a chemotactic cytokine produced by macrophages and tissue-cells, Ralph van Furth, 5th Leiden Conf on mononuclear phagocytes. 1992;340–5.
162. Yan XT, Tumpey TM, Kunkel SL, Oakes JE, Lausch RN. Role of MIP-2 in neutrophil migration and tissue injury in the herpes simplex virus-1-infected cornea. *Invest Ophthalmol Vis Sci.* 1998;39:1854–62.
163. Geiser T, Dewald B, Ehrenguber MU, Clarklewis I, Baggolini M. The interleukin-8-related chemotactic cytokines gro-alpha, gro-beta and gro-gamma activate human neutrophil and basophil leukocytes. *J Biol Chem.* 1993;268:15419–24.
164. Thomsen MK, Larsen CG, Thomsen HK, Kirstein D, Skaknielsen T, Ahnfeldtronne I, et al. Recombinant human interleukin-8 is a potent activator of canine neutrophil aggregation, migration and leukotriene-B4 biosynthesis. *J Invest Dermatol.* 1991;96:260–6.
165. Watanabe K, Koizumi F, Kurashige Y, Tsurufuji S, Nakagawa H. Rat CINC, a member of the interleukin-8 family, is a neutrophil-specific chemoattractant *in vivo*. *Exp Mol Pathol.* 1991;55:30–7.
166. Franchini M, Gill U, von Fellenberg R, Bracher VD. Interleukin-8 concentration and neutrophil chemotactic activity in bronchoalveolar lavage fluid of horses with chronic obstructive pulmonary disease following exposure to hay. *Am J Vet Res.* 2000;61:1369–74.
167. Franchini M, Gill U, Akens MK, Fellenberg RV, Bracher V. The role of neutrophil chemotactic cytokines in the pathogenesis of equine

- chronic obstructive pulmonary disease (COPD). *Vet Immunol Immunopathol.* 1998;66:53–65.
168. VanWetering S, MannesseLazeroms SPG, Dijkman JH, Hiemstra PS. Effect of neutrophil serine proteinases and defensins on lung epithelial cells: modulation of cytotoxicity and IL-8 production. *J Leukoc Biol.* 1997;62:217–26.
 169. Dallegri F, Ottonello L, Bevilacqua M. Possible modes of action of nimesulide in controlling neutrophilic inflammation. *Arzneimittelforschung.* 1995;45-2:1114–7.
 170. Cavarra E, Martorana PA, Gambelli F, de Santi M, van Even P, Lungarella G. Neutrophil recruitment into the lungs is associated with increased lung elastase burden, decreased lung elastin, and emphysema in alpha(1) proteinase inhibitor-deficient mice. *Lab Invest.* 1996;75:273–80.
 171. Couetil LL, Cardwell JM, Gerber V, Lavoie JP, Leguillette R, Richard EA. Inflammatory airway disease of horses-revised consensus statement. *J Vet Intern Med.* 2016;30:503–15.
 172. Gilkerson JR, Bailey KE, Diaz-Mendez A, Hartley CA. Update on viral diseases of the equine respiratory tract. *Vet Clin North Am Equine Pract.* 2015;31:91–104.
 173. Wood JLN, Newton JR, Chanter N, Mumford JA. Inflammatory airway disease, nasal discharge and respiratory infections in young British racehorses. *Equine Vet J.* 2005;37:236–42.
 174. Allen KJ, Tremaine WH, Franklin SH. Prevalence of inflammatory airway disease in national hunt horses referred for investigation of poor athletic performance. *Equine Vet J.* 2006;38(Suppl 36):529–34.
 175. Schlocker N, Gerberbretschler R, Vonfellenberg R. Equine herpesvirus-2 in pulmonary macrophages of horses. *Am J Vet Res.* 1995;56:749–54.
 176. Beekman L, Tohver T, Léguillette R. Comparison of cytokine mRNA expression in the bronchoalveolar lavage fluid of horses with inflammatory airway disease and bronchoalveolar lavage mastocytosis or neutrophilia using REST software analysis. *J Vet Intern Med.* 2012;26:153–61.
 177. Wilson ME, McCandless EE, Olszewski MA, Robinson NE. Alveolar macrophage phenotypes in severe equine asthma. *Vet J.* 2020;256:105436.
 178. Frellstedt L, Waldschmidt I, Gosset P, Desmet C, Pirottin D, Bureau F, et al. Training modifies innate immune responses in blood monocytes and in pulmonary alveolar macrophages. *Am J Respir Cell Mol Biol.* 2014;51:135–42.
 179. Roldal SL, Love DN, Bailey GD, Rose RJ. The effect of high intensity exercise on the functional capacity of equine pulmonary alveolar macrophages and BAL-derived lymphocytes. *Res Vet Sci.* 2000;68:249–53.
 180. Karagianni AE, Summers KM, Couroucé A, Depecker M, McGorum BC, Hume DA, et al. The effect of race training on the basal gene expression of alveolar macrophages derived from standardbred racehorses. *J Equine Vet Sci.* 2019;75:48–54.
 181. Wood JLN, Burrell MH, Roberts CA, Chanter N, Shaw Y. *Streptococci* and *Pasturella spp.* associated with disease of the equine lower respiratory - tract. *Equine Vet J.* 1993;25:314–8.
 182. Burrell MH, Wood JLN, Whitwell KE, Chanter N, Mackintosh ME, Mumford JA. Respiratory disease in thoroughbred horses in training: the relationships between disease and viruses, bacteria and environment. *Vet Rec.* 1996;139:308–13.
 183. Laan T, Bull S, Pirie S, Fink-Gremmels J. Evaluation of cytokine production by equine alveolar macrophages exposed to lipopolysaccharide, *Aspergillus fumigatus*, and a suspension of hay dust. *Am J Vet Res.* 2005;66:1584–9.
 184. Werners AH, Bryant CE. Pattern recognition receptors in equine endotoxaemia and sepsis. *Equine Vet J.* 2012;44:490–8.
 185. Suri SS, Janardhan KS, Parbhakar O, Caldwell S, Appleyard G, Singh B. Expression of Toll-like receptor 4 and 2 in horse lungs. *Vet Res.* 2006;37:541–51.
 186. Henneke P, Takeuchi O, Malley R, Lien E, Ingalls RR, Freeman MW, et al. Cellular activation, phagocytosis, and bactericidal activity against group B streptococcus involve parallel myeloid differentiation factor 88-dependent and independent signaling pathways. *J Immunol.* 2002;169:3970–7.
 187. Fairbairn L, Kapetanovic R, Sester DP, Hume DA. The mononuclear phagocyte system of the pig as a model for understanding human innate immunity and disease. *J Leukoc Biol.* 2011;89:855–71.
 188. Fan J, Frey RS, Malik AB. TLR4 signaling induces TLR2 expression in endothelial cells via neutrophil NADPH oxidase. *J Clin Invest.* 2003;112:1234–43.
 189. Waldschmidt I, Pirottin D, Art T, Audigie F, Bureau F, Tosi I, et al. Experimental model of equine alveolar macrophage stimulation with TLR ligands. *Vet Immunol Immunopathol.* 2013;155:30–7.
 190. Rutz M, Metzger J, Gellert T, Lupp P, Lipford GB, Wagner H, et al. Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner. *Eur J Immunol.* 2004;34:2541–50.
 191. Schneberger D, Caldwell S, Suri SS, Singh B. Expression of toll-like receptor 9 in horse lungs. *Anat Rec.* 2009;292:1068–77.
 192. Rutherford MS, Witsell A, Schook LB. Mechanisms generating functionally heterogeneous macrophages - chaos revisited. *J Leukoc Biol.* 1993;53:602–18.
 193. Schneberger D, Caldwell S, Kanthan R, Singh B. Expression of Toll-like receptor 9 in mouse and human lungs. *J Anat.* 2013;222:495–503.
 194. Singh B, de la Concha-Bermejillo A. Gadolinium chloride removes pulmonary intravascular macrophages and curtails the degree of ovine lentivirus-induced lymphoid interstitial pneumonia. *Int J Exp Pathol.* 1998;79:151–62.
 195. Schneberger D, Sethi RS, Singh B. Comparative view of lung vascular endothelium of cattle, horses, and water buffalo. *Adv Anat Embryol Cell Biol.* 2018;228:21–39.
 196. Parbhakar OP, Duke T, Townsend HGG, Singh B. Depletion of pulmonary intravascular macrophages partially inhibits lipopolysaccharide-induced lung inflammation in horses. *Vet Res.* 2005;36:557–69.
 197. Aharonson-Raz K, Lohmann KL, Townsend HG, Marques F, Singh B. Pulmonary intravascular macrophages as proinflammatory cells in heaves, an asthma-like equine disease. *Am J Physiol Lung Cell Mol Physiol.* 2012;303:L189–L198.
 198. Harrison JM, Qvanstrom LM, Robinson AR, Wobeser B, Anderson SL, Singh B. Expression of von Willebrand factor, pulmonary intravascular macrophages, and Toll-like receptors in lungs of septic foals. *J Vet Sci.* 2017;18:17–23.
 199. Klingensmith WC 3rd, Ryerson TW. Lung uptake of 99m Tc-sulfur colloid. *J Nucl Med.* 1973;14:201–4.
 200. Klingensmith WC 3rd, Yang SL, Wagner HN Jr. Lung uptake of Tc-99m sulfur colloid in liver and spleen imaging. *J Nucl Med.* 1978;19:31–5.
 201. Warner AE, Mulina RM, Bellows CF, Brain JD. Endotoxemia enhances pulmonary mononuclear cell uptake of circulating particles and pathogens in a species without pulmonary intravascular macrophages. *Chest.* 1994;105:50S–51S.
 202. Shih WJ, Domstad PA, Friedman B, DeLand FH. Intrathoracic abnormalities demonstrated by technetium-99m sulfur colloid imaging. *Clin Nucl Med.* 1986;11:792–6.
 203. Schneemann M, Schoedon G, Hofer S, Blau N, Guerrero L, Guerrero L, et al. Nitric oxide synthase is not a constituent of the antimicrobial armature of human mononuclear phagocytes. *J Infect Dis.* 1993;167:1358–63.
 204. Schneemann M, Schoedon G. Macrophage biology and immunology: man is not a mouse. *J Leukoc Biol.* 2007;81:579.
 205. Mak IW, Evaniew N, Ghert M. Lost in translation: animal models and clinical trials in cancer treatment. *Am J Transl Res.* 2014;6:114–8.

206. Heinz S, Haehnel V, Karaghiosoff M, Schwarzfischer L, Müller M, Krause SW, et al. Species-specific regulation of Toll-like receptor 3 genes in men and mice. *J Biol Chem*. 2003;278:21502–9.
207. Dinges MM, Schlievert PM. Comparative analysis of lipopolysaccharide-induced tumor necrosis factor alpha activity in serum and lethality in mice and rabbits pretreated with the staphylococcal superantigen toxic shock syndrome toxin 1. *Infect Immun*. 2001;69:7169–72.
208. Sauter C, Wolfensberger C. Interferon in human serum after injection of endotoxin. *Lancet*. 1980;2:852–3.
209. Burrows GE. Dose-response of ponies to parenteral *Escherichia coli* endotoxin. *Can J Comp Med*. 1981;45:207–10.
210. Tateda K, Matsumoto T, Miyazaki S, Yamaguchi K. Lipopolysaccharide-induced lethality and cytokine production in aged mice. *Infect Immun*. 1996;64:769–74.
211. Freeman TC, Ivens A, Baillie JK, Beraldi D, Barnett MW, Dorward D. A gene expression atlas of the domestic pig. *BMC Biol*. 2012;10(1):90.
212. Bryant CE, Spring DR, Gangloff M, Gay NJ. The molecular basis of the host response to lipopolysaccharide. *Nat Rev Microbiol*. 2010;8:8–14.
213. Walsh C, Gangloff M, Monie T, Smyth T, Wei B, McKinley TJ, et al. Elucidation of the MD-2/TLR4 interface required for signaling by lipid IVA. *J Immunol*. 2008;181:1245–54.
214. Kovach NL, Yee E, Munford RS, Raetz CR, Harlan JM. Lipid IVA inhibits synthesis and release of tumor necrosis factor induced by lipopolysaccharide in human whole blood ex vivo. *J Exp Med*. 1990;172:77–84.
215. Vogel SN, Madonna GS, Wahl LM, Rick PD. In vitro stimulation of C3H/HeJ spleen cells and macrophages by a lipid A precursor molecule derived from *Salmonella typhimurium*. *J Immunol*. 1984;132:347–53.
216. Lohmann KL, Vandenplas ML, Barton MH, Bryant CE, Moore JN. The equine TLR4/MD-2 complex mediates recognition of lipopolysaccharide from *Rhodobacter sphaeroides* as an agonist. *J Endotoxin Res*. 2007;13:235–42.
217. Irvine KL, Hopkins LJ, Gangloff M, Bryant CE. The molecular basis for recognition of bacterial ligands at equine TLR2, TLR1 and TLR6. *Vet Res*. 2013;44:50.
218. Silva NM, Rodrigues CV, Santoro MM, Reis LFL, Alvarez-Leite JI, Gazzinelli RT. Expression of indoleamine 2,3-dioxygenase, tryptophan degradation, and kynurenine formation during in vivo infection with *Toxoplasma gondii*: induction by endogenous gamma interferon and requirement of interferon regulatory factor 1. *Infect Immun*. 2002;70:859–68.
219. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. *Nat Rev Immunol*. 2004;4:762–74.
220. Hammond RA, Hannon R, Freaun SP, Armstrong SJ, Flower RJ, Bryant CE. Endotoxin induction of nitric oxide synthase and cyclooxygenase-2 in equine alveolar macrophages. *Am J Vet Res*. 1999;60:426–31.
221. Johnson JP, Moore LA, Cogswell AM, Allen GK. Activation of equine pulmonary alveolar macrophages does not yield nitric oxide. (Abstract # 16) *J Vet Int Med*. 1997;11:107.
222. Lunney JK. Advances in swine biomedical model genomics. *Int J Biol Sci*. 2007;3:179–84.
223. Spurlock ME, Gabler NK. The development of porcine models of obesity and the metabolic syndrome. *J Nutr*. 2008;138:397–402.
224. Snapper JR. Large animal-models of asthma. *Am Rev Respir Dis*. 1986;133:351–2.
225. Bureau F, Delhalle S, Bonizzi G, Fievez L, Dogne S, Kirschvink N, et al. Mechanisms of persistent NF-kappa B activity in the bronchi of an animal model of asthma. *J Immunol*. 2000;165:5822–30.
226. Couetil LL, Hoffman AM, Hodgson J, Buechner-Maxwell V, Viel L, Wood JLN, et al. Inflammatory airway disease of horses. *J Vet Intern Med*. 2007;21:356–61.
227. Sitterle E, Frealle E, Foulet F, Cabaret O, Cremer G, Guillot J, et al. *Trichophyton bulbosum*: a new zoonotic dermatophyte species. *Med Mycol*. 2012;50:305–9.
228. Traversa D, Otranto D, Milillo P, Latrofa MS, Giangaspero A, Di Cesare A, et al. *Giardia duodenalis* sub-Assemblage of animal and human origin in horses. *Infect Genet Evol*. 2012;12:1642–6.
229. Cardwell JM, Wood JL, Smith KC, Newton JR. Descriptive results from a longitudinal study of airway inflammation in British National Hunt racehorses. *Equine Vet J*. 2011;43:750–5.
230. Cardwell JM, Smith KC, Wood JL, Newton JR. Infectious risk factors and clinical indicators for tracheal mucus in British National Hunt racehorses. *Equine Vet J*. 2014;46:150–5.
231. Walsh NP, Gleeson M, Shephard RJ, Gleeson M, Woods JA, Bishop NC, et al. Position statement part one: immune function and exercise. *Exerc Immunol Rev*. 2011;17:6–63.
232. Nieman DC, Wentz LM. The compelling link between physical activity and the body's defense system. *J Sport Health Sci*. 2019;8:201–17.
233. Petersen JL, Mickelson JR, Cothran EG, Andersson LS, Axelsson J, Bailey E, et al. Genetic diversity in the modern horse illustrated from genome-wide SNP data. *PLoS One*. 2013;8:e54997.
234. Raudsepp T, Finno CJ, Bellone RR, Petersen JL. Ten years of the horse reference genome: insights into equine biology, domestication and population dynamics in the post-genome era. *Anim Genet*. 2019;50(6):569–97.
235. Wade CM, Giulotto E, Sigurdsson S, Zoli M, Gnerre S, Imsland F, et al. Genome sequence, comparative analysis, and population genetics of the domestic horse. *Science*. 2009;326:865–7.
236. Gerber V, Tessier C, Marti E. Genetics of upper and lower airway diseases in the horse. *Equine Vet J*. 2014;47:390–7.
237. Jost U, Klukowska-Rötzler J, Dolf G, Swinburne JE, Ramseyer A, Bugno M, et al. A region on equine chromosome 13 is linked to recurrent airway obstruction in horses. *Equine Vet J*. 2007;39:236–41.
238. Swinburne JE, Bogle H, Klukowska-Rötzler J, Drögemüller M, Leeb T, Temperton E, et al. A whole-genome scan for recurrent airway obstruction in Warmblood sport horses indicates two positional candidate regions. *Mamm Genome*. 2009;20:504–15.
239. Howard TD, Koppelman GH, Xu J, Zheng SL, Postma DS, Meyers DA, et al. Gene-gene interaction in asthma: IL4RA and IL13 in a Dutch population with asthma. *Am J Hum Genet*. 2002;70:230–6.
240. Mújica-López KI, Flores-Martínez SE, Ramos-Zepeda R, Castañeda-Ramos SA, Gazca-Aguilar A, García-Pérez J, et al. Association analysis of polymorphisms in the interleukin-4 receptor (alpha) gene with atopic asthma in patients from western Mexico. *Eur J Immunogenet*. 2002;29:375–8.
241. Ainsworth DM, Grunig G, Matychak MB, Young J, Wagner B, Erb HN, et al. Recurrent airway obstruction (RAO) in horses is characterized by IFN-gamma and IL-8 production in bronchoalveolar lavage cells. *Vet Immunol Immunopathol*. 2003;96:83–91.
242. Lavoie JP, Maghni K, Desnoyers M, Taha R, Martin JG, Hamid QA. Neutrophilic airway inflammation in horses with heaves is characterized by a Th2-type cytokine profile. *Am J Respir Crit Care Med*. 2001;164:1410–3.
243. Abdulmir AS, Hafidh RR, Abubakar F, Abbas KA. Changing survival, memory cell compartment, and T-helper balance of lymphocytes between severe and mild asthma. *BMC Immunol*. 2008;9:73.
244. Milenkovic D, Oustry-Vaiman A, Lear TL, Billault A, Mariat D, Piumi F, et al. Cytogenetic localization of 136 genes in the horse: comparative mapping with the human genome. *Mamm Genome*. 2002;13:524–34.
245. Steinbach F, Stark R, Ibrahim S, Abd-El Gawad E, Ludwig H, Walter J, et al. Molecular cloning and characterization of markers and cytokines for equid myeloid cells. *Vet Immunol Immunopathol*. 2005;108:227–36.

246. Tompkins D, Hudgens E, Horohov D, Baldwin CL. Expressed gene sequences of the equine cytokines interleukin-17 and interleukin-23. *Vet Immunol Immunopathol.* 2010;133:309–13.
247. Hudgens E, Tompkins D, Boyd P, Lunney JK, Horohov D, Baldwin CL. Expressed gene sequence of the IFN gamma-response chemokine CXCL9 of cattle, horses, and swine. *Vet Immunol Immunopathol.* 2011;141:317–21.
248. Roberts WM, Look AT, Roussel MF, Sherr CJ. Tandem linkage of human CSF-1 receptor (C-FMS) and PDGF receptor genes. *Cell.* 1988;55:655–61.
249. Yarden Y, Ullrich A. Growth factor receptor tyrosine kinases. *Annu Rev Biochem.* 1988;57:443–78.
250. Beck J, Chowdhary BP, Brenig B. Assignment of the equine colony stimulating factor 1 receptor gene (CSF1R) to equine chromosome 14q15->q16 (ECA14q15->q16) by in situ hybridization and radiation hybrid panel mapping. *Cytogenet Genome Res.* 2005;109:533.
251. Chowdhary BP, Raudsepp T, Kata SR, Goh G, Millon LV, Allan V, et al. The first-generation whole-genome radiation hybrid map in the horse identifies conserved segments in human and mouse genomes. *Genome Res.* 2003;13:1258.
252. Raudsepp T, Fronicke L, Scherthan H, Gustavsson I, Chowdhary BP. Zoo-FISH delineates conserved chromosomal segments in horse and man. *Chromosome Res.* 1996;4:218–25.
253. Raudsepp T, Kata SR, Piumi F, Swinburne J, Womack JE, Skow LC, et al. Conservation of gene order between horse and human X chromosomes as evidenced through radiation hybrid mapping. *Genomics.* 2002;79:451–7.
254. Roenne M. Putative fragile sites in the horse karyotype. *Hereditas.* 1992;17:127–36.
255. Hume DA, Summers KM, Raza S, Baillie JK, Freeman TC. Functional clustering and lineage markers: Insights into cellular differentiation and gene function from large-scale microarray studies of purified primary cell populations. *Genomics.* 2010;95:328–38.
256. Mabbott NA, Kenneth Baillie J, Hume DA, Freeman TC. Meta-analysis of lineage-specific gene expression signatures in mouse leukocyte populations. *Immunobiology.* 2010;215:724–36.
257. Young R, Lefevre L, Bush SJ, Joshi A, Singh SH, Jadhav SK, et al. A gene expression atlas of the domestic water buffalo (*Bubalus bubalis*). *Front Genet.* 2019;10:668.
258. Graham NS, Clutterbuck AL, James N, Lea RG, Mobasheri A, Broadley MR, et al. Equine transcriptome quantification using human GeneChip arrays can be improved using genomic DNA hybridisation and probe selection. *Vet J.* 2010;186:323–7.
259. Huang L, Zhu W, Saunders CP, MacLeod JN, Zhou M, Stromberg AJ, et al. A novel application of quantile regression for identification of biomarkers exemplified by equine cartilage microarray data. *BMC Bioinformatics.* 2008;9(1):300.
260. Coleman SJ, Zeng Z, Wang K, Luo S, Khrebtukova I, Mienaltowski MJ, et al. Structural annotation of equine protein-coding genes determined by mRNA sequencing. *Anim Genet.* 2010;41:121–30.
261. Kalbfleisch TS, Rice ES, DePriest MS Jr, Walenz BP, Hestand MS, Vermeesch JR, et al. Improved reference genome for the domestic horse increases assembly contiguity and composition. *Commun Biol.* 2018;1:197.
262. Bright L, Burgess S, Chowdhary B, Swiderski C, McCarthy F. Structural and functional-annotation of an equine whole genome oligoarray. *BMC Bioinformatics.* 2009;10:S8.
263. Coleman SJ, Zeng Z, Hestand MS, Liu J, Macleod JN. Analysis of unannotated equine transcripts identified by mRNA Sequencing. *PLoS One.* 2013;8:e70125.
264. Andersson L, Archibald AL, Bottema CD, Brauning R, Burgess SC, Burt DW, et al. Coordinated international action to accelerate genome-to-phenome with FAANG, the Functional Annotation of Animal Genomes project. *Genome Biol.* 2015;16:57.
265. Morrison DC, Ulevitch RJ. Effects of bacterial endotoxins on host mediation systems - review. *Am J Pathol.* 1978;93:526–617.
266. Capomaccio S, Cappelli K, Spinsanti G, Mencarelli M, Muscettola M, Felicetti M, et al. Athletic humans and horses: comparative analysis of interleukin-6 (IL-6) and IL-6 receptor (IL-6R) expression in peripheral blood mononuclear cells in trained and untrained subjects at rest. *BMC Physiol.* 2011;11(1):3.
267. Langley R, Morris T. That horse bit me: zoonotic infections of equines to consider after exposure through the bite or the oral/nasal secretions. *J Agromed.* 2009;14:370–81.
268. Shin YS, Takeda K, Gelfand EW. Understanding asthma using animal models. *Allergy Asthma Immunol Res.* 2009;1:10–8.
269. Wall RJ, Shani M. Are animal models as good as we think? *Theriogenology.* 2008;69:2–9.
270. Abarbanell AM, Herrmann JL, Weil BR, Wang Y, Tan J, Moberly SP, et al. Animal models of myocardial and vascular injury. *J Surg Res.* 2010;162:239–49.
271. Yates AD, Achuthan P, Akanni W, Allen J, Allen J, Alvarez-Jarreta J, et al. Ensembl 2020. *Nucleic Acids Res.* 2020;48:D682–D688.
272. Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, et al. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. *Mol Syst Biol.* 2011;7:539.

How to cite this article: Karagianni AE, Lisowski ZM, Hume DA, Scott Pirie R. The equine mononuclear phagocyte system: The relevance of the horse as a model for understanding human innate immunity. *Equine Vet J.* 2020;00:1–19. <https://doi.org/10.1111/evj.13341>